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ABSTRACT
The overall objective of this thesis work was to develop new insights into the etiology of
scleroderma, a human systemic autoimmune disease, by analyzing the autoantibodies to
centrosome antigens that develop durng the disease. Centrosomes are perinuclear.
organelles that form microtubule arrays, including mitotic spindles that ensure the faithful
segregation of chromosomes during mitosis.
These studies used a novel methodology to determine the prevalence of anti-centrosome
autoantibodies in patients with scleroderma. Recombinant centrosome antigens were used
to determine the antigenic specificity of anti-centrosome antibody subsets by
immunoblotting. Centrosome marker antibodies were used in indirect
immunofluorescence assays to distinguish centrosomes within the polymorphic staining
pattern frequently given by scleroderma sera. We found that 43% of patients are
autoreactive to centrosomes, a prevalence higher than has been reported for any other
scleroderma auto antigen. Half of the centrosome-positive patients also had autoantibodies
against other antigens used in scleroderma diagnosis. However, in the remaining half of
these patients, anti-centrosome antibodies represented the sole class of autoantibodies
that was detectable. Anti-centrosome antibodies were detected in only a small percentage
of normal individuals and patients with other connective tissue diseases.
These data suggest that anti-centrosome autoantibodies may represent a new diagnostic
tool in scleroderma. Upon examination of anti-centrosome autoantibody development in
an animal model, it appeared that this autoantibody specificity may develop in mice as a
consequence of an infection.
An infectious agent was isolated by plaque-formation from carier mice. Furher
characterization of the infectious agent was undertaken to obtain information on its
physical, morphological and cytopathological properties. The infectious agent was
identified by sequence and unique antigenic properties to be homologous to the pig
pathogen Mycoplasma hyorhinis. When reintroduced into naive mice, the murine
mycoplasma triggered anti-centrosome autoantibody development. While anti-
centrosome autoantibodies of IgM isotype are part of the repertoire of naive
unimmunzed mice, mycoplasma infection specifically triggered the development of anti-
centrosome IgG. Moreover, centrosome autoreactivity was prevented by antibiotic
treatment. The autoantibody response evolved to recruit additional specificities , having
IgM isotypes, reactive to endoplasmic reticulum-associated auto antigens.
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CHAPTER I
INTRODUCTION
A. Specific Aims
The overall goal of this dissertation was to fuher our understanding of scleroderma, a
human connective tissue disease. Our approach was based on the principle that
elucidating the mechanism that leads to the development of a key scleroderma feature
like unique autoantibodies wil provide insights into the as yet unown etiology of the
disease. The goal of this work was to analyze a specific subset of autoantibodies that
recognize proteins of the centrosome, and to examine the loss of tolerance to centrosome
autoantigens in human scleroderma patients and in a murine model demonstrating similar
autoantibody development. When autoantibodies to centro somes were found to develop
in mice exposed to an infectious agent, the overall objectives of the study were expanded
to include the isolation, identification and characterization of that infectious agent and to
demonstrate that naive mice develop characteristic centrosome autoantibodies when
infected with that agent.
The specific aims of this study were:
1. To characterize autoantibodies to centro somes that develop in patients with
scleroderma; this required the following:
to design sensitive and specific assays to detect human anti-centrosome
autoantibodies
to determine anti-centrosome autoantibody prevalence in scleroderma
to determine if anti-centrosome autoantibodies were unique to scleroderma
patients or appeared in patients with other connective tissue diseases or in
normal individuals
to define the diagnostic and prognostic significance of anti-centrosome
autoantibodies detected in scleroderma
2. To develop an animal model for the study of anti-centrosome autoantibodies. This
aspect of my work included:
the isolation of a putative infectious agent from autoantibody:.positive mice
the identification of the isolated infectious agent by genome sequence and
antigenic properties
the characterization of the physical, morphological and cytopathological
properties of the infectious agent in vitro
the determination of the ability of the infectious agent to induce anti-
centrosome autoantibodies in vivo
3. To establish the conditions necessary to induce an infection-dependent autoantibody
response in mice including the determination of:
the route of infection
the kinetics of the response
the isotypes recruited during the response
the autoantibody specificities that developed upon infection
The following introductory material will place the objectives of this study in the context
of our curent knowledge of the mechanisms of autoantibody development, the role of
autoantibodies in human systemic autoimmune diseases, and the induction of
autoantibodies as a consequence of infection.
B. Mechanisms of Autoantibody Development
The development of high-titer autoantibodies is a consistent feature of many human
autoimmune diseases. However, autoantibodies can be also found in healthy individuals
suggesting important differences disease-related autoantibodies andbetween
autoantibodies with roles in normal physiology.
Autoantibodies in Normal Physiology. Low titered autoreactive immunoglobulins
called "natural autoantibodies" and produced by CD5-expressing B cells, are readily
detected in the sera of healthy individuals (Stall et aI., 1996). Natural antibodies are
mainly of the IgM isotype and use variable region genes that are not somatically
hypermutated, whereas disease-associated autoantibodies have switched to multiple
isotypes and have undergone somatic hypermutation (Bona and Rothfield, 1994;
Feldmann et aI., 1996; Kotzin, 1996; Stall et aI., 1996). Natural autoantibodies are not
pathogenic and are thought to fulfill a housekeeping fuction, e.g. clearing modified self-
antigens that result from cellular apoptosis or oxidized lipoprotein (Shaw et aI. , 2000). B
cells producing natural autoantibodies are likely positively selected on self-antigen, and
they frequently produce antibodies that cross-react with bacterial antigens (Hayakawa et
aI. , 1999; Shaw et aI. , 2000). This reactivity to non-self antigen postulates an additional
role for natural antibody in innate immunity. Indeed, a natural antibody reactive to both
self and non-self antigens has been shown to provide optimal protection from infection
with virulent bacteria (Briles et aI. , 1982; Shaw et aI. , 2000).
Natural autoantibody secretion can be induced by stimulation of receptors other than the
cell antigen receptor. Bacterial lipopolysaccharide signallng through Toll-like
receptors induces autoantibody secretion by CD5-positive B cells (Hayakawa et aI. , 1999;
Kawai et aI. , 1999). Similarly, CpG dinucleotide-containing bacterial nucleic acid can
also induce polyclonal B cell activation(Hemmi et aI. , 2000). It is likely, therefore , that
natural autoantibody production can be induced by a number of non-self components.
As mentioned previously, pathogenic autoantibodies found in autoimmune disease are
class switched and somatically mutated. Paradoxically, these processes normally occur in
germinal centers, and natural auto reactive B cells and conventional autoreactive B cells
are normally excluded from entering germinal centers in the presence of cognate self-
antigen (Cyster et aI. , 1994; Stall et aI. , 1996). However, a very recent paper showed that
in an autoimmune mouse strain autoreactive B cells undergo active somatic
hypermutation outside of germinal centers (Wiliam et aI., 2002). This suggests that
autoantibodies result during autoimmune disease upon abnormal recruitment of
autoreactive B cells into germinal centers or due to ectopic isotype switching and somatic
hypermutation, outside of germinal centers.
It is possible that disease-related autoantibodies result from the pathologic somatic
hypermutation of natural autoreactive B cells. Such an event is implied by the striking
similarity of specificities recognized by the natural autoantibody repertoire to those found
in the high titer autoantibodies developed by systemic autoimmune disease patients
(Hansen et aI. , 2000). Alternatively, autoantibody production during autoimmune disease
may result from pathologic somatic hypermutation and/or surival of conventional
autoreactive B lymphocytes. Autoantibody responses of conventional B lymphocytes wil
be outlined below.
Autoantibodies Can Develop Due to B Cell Epitope Mimicry. During Immune
responses to foreign antigens conventional B lymphocytes routinely generate
immunoglobulins that cross-react with self and non-self epitopes. In one study, lupus-like
antibodies to double stranded DNA (dsDNA) of IgG isotype resulted upon immunization
with phosphorylcholine, a pneumococcal cell wall component (Ray et aI. , 1996).
Moreover monoclonal andantibody with dual specificity for dsDNA
phosphory1choline is able to recognize a third epitope, a peptide from a phage display
library (Gaynor et aI. , 1997). Immunization with this peptide results in the development
of anti-dsDNA antibodies (Putterman and Diamond, 1998). During infection , somatically
mutated autoreactive antibodies are produced by a significant fraction of the B cells
recruited into the immune response (Ray et aI. , 1996). These autoantibodies can trigger
pathology similar to that found in systemic lupus erythematosus (SLE) (Putterman and
Diamond, 1998). However, autoreactive B cells activated during immune responses to
foreign antigen are normally short-lived and destined to undergo apoptosis (Ray et aI.
1996). Induction of a milieu supporting the survival of autoreactive lymphocytes
activated as a consequence of infection could account for durable autoantibody
development and autoimmune pathogenesis. Under these circumstances, conventional B
cells can generate autoantibodies as a consequence of infection , due to the homology
between self and non-self epitopes.
Autoantibody Responses Can Be Initiated by Immunogenic, Although Previously
Cryptic B Cell Epitopes and Can Diversify by Epitope Spreading. Autoimmune
disease patients develop autoantibodies to distinct epitopes found on interacting proteins
of multimolecular complexes (Craft and Fatenejad, 1997). The presence of multiple
antigenic targets in a multimolecular complex indicates that the entire complex is taken
up and individual components are presented on the same antigen-presenting cell. Several
studies also reported that intact, native macromolecular complexes are more frequently
targeted by patient autoantibodies than the individual antigen components of which they
are comprised, and many patient autoantibodies recognize conformational determinants
(Craft and Fatenejad, 1997) (Kasturi et aI. , 1995).
Although the auto antigens of multimolecular complexes targeted in a systemic
autoimmune disease may have very distinct subcellular locations, they frequently cluster
together within vesicular surface structures produced in apoptosing cells (Cascio la-Rosen
et aI. , 1994). During virus-induced apoptosis, viral antigens co-cluster with auto antigens
of systemic autoimmune diseases, providing a mechanism by which infection may render
auto antigens immunogenic (Rosen et aI., 1995). This proximity, combined with
apoptosis-specific cleavage of auto antigens by proteases or reactive oxygen species , may
explain the production of new immunogenic, previously cryptic epitopes (Cascio la-Rosen
et aI. , 1995).
Autoantibodies to complex antigens first seem to react with one or a few epitopes and
evolve in predictable ways to include more epitopes, defining a phenomenon named
epitope spreading (Shlomchik et aI. , 2001). An example of this process is provided by
native small nuclear ribonucleoprotein (snRP) paricles, which are normally not
immunogenic. However, after priming mice with either of two self-peptides encoded by
snRNP antigens, challenge with the native murine snRP produced antibodies that
immunoprecipitated snRP (Bockenstedt et aI., 1995). This suggests that loss of
tolerance to self can be initiated in the absence of foreign antigen by the abnormal
processing and presentation of one initiating epitope; subsequently, epitope spreading
within the same molecule (intramolecularly) or within neighboring molecules
(intermolecularly) can account for the amplification of the autoantibody response
(Bockenstedt et aI. , 1995; Topfer et aI. , 1995). Epitope spreading might be induced by
activated autoreactive T cells (Craft and Fatenejad, 1997).
Normal B Cell Tolerance May Be Broken by the Presence of Activated Autoreactive
Cells. A role for auto reactive T cells in the development of human systemic
autoimmune disease is suggested by the presence of activated T cells at sites of chronic
inflammation (White, 1996). Also , pathogenic autoantibodies are somatically mutated
and class-switched, both normally T cell dependent processes(Craft and Fatenejad, 1997).
Moreover, T cells might directly cause tissue damage. Lupus-prone mice have interstitial
nephritis consisting of T .cell infiltrates similar to human SLE patients (Shlomchik et aI.
2001). In mice prone to autoimmune disease, peripheral T cells had a significantly lower
threshold for activation than those from normal riice. As expected, genetic knockouts of
T or B cells showed a requirement for both cell subsets for the development of SLE.
A direct demonstration of the role of T cells in systemic autoimmune pathogenesis was
provided when it was shown that mice expressing a transgenic autoreactive T cell
receptor (TCR) developed rheumatoid arthritis (Kouskoff et aI. , 1996). T cells in this
system help autoreactive B cells, which, in turn, secrete pathogenic autoantibodies.
Autoreactive B cells are normally quiescent in the absence of the transgenic T cells, and
mice do not spontaneously develop rheumatoid arthritis. The fact that disease is initiated
in this system by a homogeneous T cell population bearing the same transgenic TCR
indicates that a critical number of autoreactive T cells are mandatory for pathogenesis.
Once initiated, pathology is mediated entirely by autoreactive immunoglobulin, in
conjunction with complement (Korganow et aI. , 1999).
In other studies T cells have been shown to influence autoantibody-mediated
pathogenesis by acting on natural autoreactive B cells, also called B 1 cells. Some T
helper 2 (TH2) cytokines (IL-5 and IL- , but not IL-4) induce Bl cell differentiation 
autoantibody-producing cells (Nisitani et aI. , 1995). In another study y6 T cells induce
differentiation of B 1 cells to autoantibody-producing cells by non-cognate interactions
(Watanabe et aI. , 2000). The development of autoreactive Band T cells with an activated
phenotype is increasingly attributed to genetic factors.
Multiple Genetic Factors Faciltate Autoantibody Production. Autoantibody
development has been observed in mice with homozygous mutations of the following:
complement components Cl , C2 or C4; receptors for complement CR2; cell death
mediators Fas, Fas ligand and perforin; or mediators of negative signallng like the
growth arest and DNA damage-inducible gene (Gadd45a), protein kinase C6 (PKC6)
and transcription factor T -bet (Chen et aI. , 2000; Ishigatsubo et aI. , 1988; Miyamoto et
aI. , 2002; Peng et aI. , 1998; Peng et aI. , 2002; Pro deus et aI. , 1998; Salvador et aI. , 2002;
Taylor et aI. , 2000). Mutations that impede the clearance of apoptotic cells also trigger
autoantibody development. Mice deficient in the serum amyloid P (SAP) component
which binds degraded chromatin fragments of apoptotic and necrotic cells, develop anti-
nuclear antibodies (Bickerstaff et aI. , 1999). Similarly, mice lacking a fuctional "Mer
membrane tyrosine kinase develop anti-nuclear autoantibodies and a lupus-like syndrome
as a consequence of impaired phagocytosis and clearance of apoptotic cells (Cohen et aI.
2002; Scott et aI., 2001). Components of the classical complement pathway also
paricipate in the clearance of apoptotic cell debris, and their absence, consistently
detected in autoimmune disease patients, may contribute to the development of
autoantibodies (Taylor et aI., 2000). Autoreactive antibodies also develop in mice
transgenic for B lymphocyte activators like CDI9 , which regulate the signaling threshold
of autoreactive B cells (Sato et aI. , 2000). Autoantibody development has an incomplete
penetrance in any of these systems, pointing to the role of additional , environmental
factors for its initiation.
Pathogenic Role of Autoantibodies. Autoantibodies have characteristics that reflect on
the mechanism of disease development and can be pathogenic themselves. It is therefore
important to define the autoantibody properties that are necessary and sufficient to confer
a pathogenic potential. In the MRL/lpr mice, pathogenic autoantibodies result from
oligoclonal , antigen-receptor-mediated expansion of B lymphocytes that became
somatically mutated (Shlomchik et aI., 1990). However, somatic mutation is not
obligatory, as un mutated antibodies were found to be both capable of high-affinity
binding to self-antigens and pathogenic (Shefner et aI., 1991). The affnity of
autoantibodies is not a predictor of their pathogenic potential (Hansen et aI. , 2000).
Moreover, low affnity autoantibodies can trigger cell lysis by binding to repetitive
structures on target cell surfaces (Fossati-Jimack et aI., 1999). The effector fuctions
mediated by the predominant isotype found in autoimmune disease may be informative of
the mechanism by which pathogenesis is mediated. For example, different isotypes have
different abilities to bind complement or F c receptors and provoke tissue damage
(Azeredo da Silveira et aI. , 2002).
Pathogenic autoantibodies are, by definition, capable of inducing specific autoimmune
disorders when transferred into normal hosts. A growing body of evidence has described
the specificities of several pathogenic autoantibodies. For example, autoantibodies to
dsDNA induce immune complex glomerulonephritis (Raz et aI. , 1989; Tsao et aI. , 1990).
Autoantibodies to glucose- phosphate isomerase , a cytoplasmic glycolytic enzyme, can
provoke rheumatoid arhritis when injected into normal mice (Matsumoto et aI., 1999).
Anti-erythrocyte and anti-thrombocyte antibodies can trigger autoimmune hemolytic
anemia and autoimmune thrombocytopenic purura, respectively (Harington et aI. , 1990;
Horwitz, 1979a; Horwitz, 1979b). In pemphigus vulgaris, anti-desmoglein antibodies
recognize an extracellular matrix component, desmoglein (Ding et aI., 1999). It is
noteworthy that, while autoantibody specificity is of key importance in defining
pathogenic potential, the intra- or extracellular localization of the auto antigen 
irrelevant. It is not clear, however, how antibodies to intracellular antigens will cause
disease. It has been suggested that such antibodies cross-react with self antigens on cell
surfaces (Lunardi et aI. , 2000).
The specificity of autoantibodies is critical for their pathogenicity in paraneoplastic
"';
syndromes. Paraneoplastic syndromes are disorders that accompany malignancies and are
mediated by pathogenic autoantibodies developed to tumor-specific neoantigens.
Pathology results from the cross-reaction of autoantibodies with normal tissues.
Antibody-induced paraneoplastic syndromes are numerous and polymorphic , suggesting
that autoantibody-mediated pathology is not fully appreciated (Lang and Vincent, 1996).
It appears that the specificity of an autoantibody is the major feature that defines its
pathogenic potential. Human autoimmune diseases are characterized by a multitude of
autoantibody specificities , as discussed below.
C. Autoantibodies in Systemic Autoimmune Diseases
Patients with systemic autoimmune diseases develop autoantibodies of many different
specificities(Sontheimer et aI. , 1992; Tan et aI. , 1988). Autoantibodies precede or parallel
disease onset and have been linked to events that initiate chronic inflammatory pathology
(Sontheimer et aI. , 1992; Tan et aI. , 1988). Each autoimmune disease has autoantibodies
with a distinct specificity profie (Hiepe et aI. , 2000).
A large number of studies have used patient sera to identify the molecular structure of
autoantigens, in hopes of determining unique as well as common, structural or functional
features that would explain their antigenicity (Galperin et aI. , 1996). The unifying feature
of autoantigens recognized in systemic autoimmunity is that they are phylogenetically
conserved, ubiquitous intracellular proteins, often assembling in larger macromolecular
complexes (Hemmerich and von Mikecz, 2000). Although some self-epitopes bear
homology to viral or bacterial sequences, the significance of these examples of
molecular mimicry" for systemic autoimmune pathogenesis has not been clarified; not
all sera from patients with antibodies to the autoantigen in question recognize the cross-
reactive epitope (Okano, 1996).
Because autoantibody induction closely parallels disease onset, autoantibody detection
reliably orients diagnosis (Hiepe et aI. , 2000). The prevalence and disease-specificity of
auto antigens have been extensively described (Galperin et aI. , 1996; Hiepe et aI. , 2000).
None of the reported autoantibody specificities is present in all patients with one systemic
autoimmune disease. While no one autoantibody specificity is exclusively associated
with a single disease, certain specificities are more characteristic of one autoimmune
disease versus another (Galperin et aI. , 1996). Within one autoimmune disease, distinct
autoantibody specificities correlate well with certain disease features or clinical subsets
of the disease and have a predictive value on disease severity (Tan et aI. , 1988).
Systemic autoimmune diseases have autoantibodies of many specificities. These occur
early during disease development and may have diagnostic significance. Similarly,
scleroderma autoantibodies show a restricted specificity for intracellular organelles, are
found early in disease, and may be of significant diagnostic or prognostic value.
8-.
Autoantibodies in Scleroderma. Scleroderma (systemic sclerosis, SSc) is a chronic
disease of unkown etiology involving the vascular system, connective tissue and
immune system. Three types of lesions are characteristic: vascular insuffciency,
excessive scar-like deposition of extracellular matrix proteins , and chronic inflammation;
these lesions develop in the skin, the musculoskeletal system and internal organs like the
lung, the gastrointestinal tract, the hear and the kidney (Jimenez et aI. , 1996; LeRoy,
1996; White , 1996).
Vascular lesions are the initiating event in scleroderma pathogenesis. Overt pathology is
preceded by an intermittent vasospasm called Raynaud's phenomenon, followed by
endothelial cell injury (LeRoy, 1996). Evidence is accumulating to support the hypothesis
that the endothelium is the target of an immune attack (Lunardi et aI. , 2000; Sgonc et aI.
1996). The fully developed vascular pathology consists of capilary destruction and a
hypertrophy of the vascular intima in arteries and arerioles. Progressive collagen
deposition is found in scleroderma and likely results from overproduction of cytokines
IL-4 or TGF-j3 during chronic inflammation (Jimenez et aI., 1996). The presence 
chronic inflammation in conjunction with the development of autoantibodies to
intracellular antigens (bearing the generic name of anti-nuclear autoantibodies, ANA) and
the lack of a single target organ assigns scleroderma to the spectrum of systemic
autoimmune diseases. Further support for scleroderma being an autoimmune disease is
provided by patients who develop overlapping syndromes, that cumulate clinical features
of scleroderma and clinical features of another systemic autoimmune disease like
systemic lupus erythematosus, Sjogren syndrome, dermatomyositis etc. In addition
scleroderma has a close clinical and histopathological resemblance with graft-versus-host
disease, a condition with an obvious immune pathogenesis (White , 1996).
Scleroderma Diagnosis. Scleroderma epidemiology is similar to that of other systemic
autoimmune diseases, in that the typical scleroderma patient is three times more likely to
be a woman between the ages of 30 and 50 years at disease onset. Scleroderma affects all
races and has a worldwide distribution. The disease has an ethnic bias, with blacks and
Choctaw Native Americans being more frequently affected(Gililand, 1998). The disease
prevalence has been reported to be between 19 and 75 per hundred thousand
individuals(Gililand, 1998).
Familial histories of scleroderma patients show that the disease recurs in families 11
times more often than expected(Tan and Arett, 2000). The occurrence within the same
family of cases with SSc and cases with other autoimmune diseases such as SLE has been
frequently reported (Tan and Arnett, 2000). Scleroderma does not have a high degree of
concordance among monozygotic twins, indicating that in addition to genetic factors
environmental factors may be also important in disease development(Tan and Arnett
2000). Interestingly, the aggregation of scleroderma autoantibodies within the families of
autoimmune disease patients is significantly higher, with first-degree relatives as well as
spouses of patients being more frequently affected (de Juan et aI., 1994). This finding,
too , suggests a role for environmental factors in scleroderma pathogenesis.
l n
Scleroderma diagnosis is established both clinically and histopathologically. The
histopathologic hallmark of scleroderma is the presence of a proliferative reaction of the
vascular intima (Jimenez et aI. 1996). Mononuclear inflammatory infiltrates
characteristic of early skin lesions are similar to infiltrates encountered in graft versus
host disease. They appear in the immediate perivascular area and consist primarily of T
cells and to a lower extent of B cells (White, 1996). The additional detection of
characteristic autoantibody specificities also greatly aids scleroderma diagnosis
(Gillland, 1998). Scleroderma is clinically heterogeneous, but has been classified in two
major clinical forms: diffuse and limited, which differ in the extent and severity of organ
involvement (van den Hoogen and de Jong, 1995). The diffuse disease has widespread
organ involvement and rapid progression, while the limited form of the disease is
confined to the skin of extremities, and internal organs are involved late.
Scleroderma Autoantibodies. Characteristic autoantibodies of scleroderma are specific
for DNA topoisomerase I , centromere proteins, and RNA polymerases I , II , or III. None
of these autoantibody specificities are found exclusively in scleroderma, but are detected
although rarely, in other autoimmune diseases as well (Galperin et aI. , 1996). Nor is any
one of these specificities detected in all scleroderma patients, but only in subsets
comprising approximately 25% of patients (Bona and Rothfield, 1994). Although
scleroderma patients respond to numerous other autoantigens, anyone of these other
specificities is at lower prevalence when compared to the above listed auto antigens (Bona
and Rothfeld, 1994; White, 1996). Some autoantibody specificities correlate with the
diffuse and limited forms of the disease and have therefore not only diagnostic, but also
prognostic significance. Anti-centromere antibodies are found primarily in limited
scleroderma, while anti-topoisomerase antibodies correlate with diffuse disease.
Furthermore, some nucleolar antigens have been proposed as markers for visceral
involvement (Okano, 1996). Autoantibodies in overlap syndromes between scleroderma
and other systemic autoimmune diseases cumulate autoantibody specificities
characteristic for each disease(Gililand, 1998).
There is limited evidence for autoantibodies being directly pathogenic in scleroderma.
Autoantibodies can induce endothelial cell apoptosis in vitro and in a scleroderma disease
model (Lunardi et aI. OOO; Sgonc et aI. , 1996). Given the precedent of autoantibody-
mediated pathology in lupus and rheumatoid arthritis , scleroderma autoantibodies may
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have the potential to cause or exacerbate disease. Alternatively, scleroderma
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autoantibodies may be epiphenomenona and occur due to the presence of activated
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autoreactive T cells. In either case, the identity of the autoantigen that initiates loss of
tolerance may be revealed by the autoantibody specificity present at disease onset and
detectable in all or the majority of patients.
Animal Models for Scleroderma. The most faithful scleroderma animal model is
provided by University of California at Davis (UCD) chicken lines (L) 200 and 206
which develop a hereditary systemic connective tissue disease that closely resembles
scleroderma (Sgonc et aI. , 1996; Van de Water et aI. , 1995). Like human scleroderma, the
avian disease is characterized by vascular occlusion, perivascular lymphocytic infiltration
of the skin and viscera and antinuclear antibodies. UCD L200 chickens also display an
abnormal thymic architecture (Van de Water et aI., 1995). Although they develop a
vigorous autoantibody response, UCD L200 chicken do not develop the autoantibody
specificities considered to be characteristic of human scleroderma(Van de Water et aI.
1995). In addition, the avian disease differs from scleroderma by being rapidly
progressive and having a high lethality(Van de Water et aI. , 1995).
Mice bearing the autosomal tight skin (tsk) mutation on chromosome 2 provide an
alternative animal model for scleroderma. These mice share with the human disease a
thickening of the skin due to increased collagen deposition and the development of
scleroderma-like autoantibodies. In contrast to the human disease however
autoantibodies in these mice occur at 8 months of age, well after the onset of the tight
skin phenotype (Bona and Rothfield, 1994; Van de Water et aI., 1995). No suitable
animal model is currently available to study the initiation of scleroderma-like
autoantibody responses.
Autoantibodies to Centrosomes in Scleroderma. One intracellular target of
autoantibodies in scleroderma is the centrosome, a peri-nuclear organelle that duplicates
during mitosis ensuring the faithful segregation of chromosomes (Doxsey, 2001).
Autoantibodies to the centrosome , to the centro somal core, the centriole, or to the mitotic
spindle have been reported in scleroderma at low prevalences 4-6% (Tuffanell et aI.
1983). Interestingly, the few scleroderma patients reported to have centrosome
autoreactivity displayed only anti -centrosome autoantibodies suggesting that
autoreactivity to centro somes may develop early, and may actually initiate scleroderma
pathogenesis (Conrad and Mehlhorn, 2000; Doxsey et aI. , 1994; Moteki et aI., 1991;
Osborn et aI. , 1982).
We developed two novel immunoassays using recombinant centrosome proteins and
centrosome-specific antibodies to demonstrate that a significant proportion of
scleroderma patients exhibit centrosome reactivity. We investigated the prevalence and
disease-specificity of anti-centrosome autoantibodies by screening a large cohort of
scleroderma patients and comparing them with normal individuals and patients with other
connective tissue diseases. We found that centrosome autoantibodies develop in 43% of
scleroderma patients, a prevalence significantly higher than has been reported for any
other scleroderma auto antigen (Gavanescu et aI., 1999). Early data on centrosome
reactivity was likely an underestimate due to assay insensitivity and to the very small
patient cohort examined(Tuffanelli et aI. , 1983). Interestingly, early data from a few case
reports also correlate anti-centrosome autoantibodies with infection (Auer-Grumbach and
Achleitner, 1994; Cimolai et aI. , 1994; Gentric et aI. , 1991; Huidbuchel et aI. , 1991; Lind
et aI. , 1988; Moteki et aI. , 1991).
D. Infection and Autoimmunity Are Characterized by Autoantibodies
. A link between infection, autoantibody production and systemic autoimmune disease has
been explored since the 1950' s(Walton, 1968).
Infection and Autoimmune Disease. The best example of infection-induced
autoimmunity is the development of human rheumatic disease syndromes , predominantly
arhritis, as a consequence of infection. Although such arthritis occurs in patients in
conjunction with clinical, serological or microbiological evidence of an antecedent
infection, no pathogen can be isolated from the affected joint (Hughes and Keat, 1994).
Moreover, this "sterile arthritis develops in multiple animal models as a direct
consequence of infection with bacteria, most notably mycoplasma (Cole et aI., 1975;
Cole et aI. , 1976; Harwick et aI. , 1973). Self-limiting autoimmune syndromes frequently
accompany human infections. Cold agglutinins (cryoglobulins) induced characteristically
by mycoplasma and hepatitis C virus trigger autoimmune hemolytic anemia and
vasculitis (Gerber et aI., 1997; Lamprecht et aI., 1999). Exacerbations of systemic
autoimmune disease subsequent to patient infection have also long been noted (Herrmann
et aI. , 2000). While no unequivocal serological or microbiological correlation between a
pathogen and a human systemic autoimmune disease has been established to date
individual disease features , especially autoantibody development, have often been linked
to infection.
Infection and Autoantibodies. Infectious agents are likely to elicit autoantibody
production by multiple mechanisms. Bacterially or virallyencoded superantigen could
drive the activation and expansion of autoreactive B or T lymphocytes (Schiffenbauer et
aI. , 1998; Silverman, 1998; Wucherpfennig, 2001). Presentation of self-antigen may be
modified during infection: infected cells undergoing apoptotic death are strong dendritic
cell activators, and these may present self antigens in an immunogenic mode; necrotic
cell death will only result in dendritic cells delivering tolerogenic stimuli (Fonteneau et
aI. , 2002; Gallucci and Matzinger, 2001). A direct demonstration of these mechanisms in
autoantibody development is stil awaited.
Molecular mimicry is one mechanism that can account for autoantibody development
during bacterial infection. Cross-reactive autoantibodies develop during Chlamydia
infection due to homology between myocardial and Chlamydia peptides (Bachmaier et
aI. 1999). Disease, i.e. autoimmune myocarditis results in this system upon
immunization with peptides homologous for either the myocardial or bacterial antigens
while bacterial nucleic acid functions as an adjuvant (Bachmaier et aI. , 1999). A direct
pathogenic role of these cross-reactive autoantibodies has not been tested in this system.
A possible pathogenic role has been examined for cross-reactive autoantibodies capable
of binding both intracellular autoantigens and viral proteins. Such antibodies have been
reported to impair the function of their target cells when added to cultures (Levin et aI.
2002; Lunardi et aI. , 2000). It is unknown whether these antibodies would be pathogenic
in vivo. Autoantibodies are likely to develop by multiple mechanisms during infection
and may induce pathology.
Infection-induced systemic autoimmune disease autoantibodies. Numerous infectious
agents have been correlated in humans with connective tissue disease autoantibodies
(Labarca et aI. , 1997; Mengarelli et aI. , 2000; Newkirk, 2002; Rider et aI. , 1997; Toyoda
et aI., 1997; Toyoda et aI., 1999). However, only lupus-like autoantibodies are
reproduced by animal models upon infection with various pathogens, most notably
viruses. For example, lupus-like ANA are induced in mice by infection with murine
cytomegalovirus (MCMV) and herpesvirus 68 (HV68), likely due to the ability of both
herpesviruses to trigger polyc1onal B cell activation (Bartholomaeus et aI. , 1988; Olding
et aI. , 1976; Price et aI. , 1993; Sangster et aI. , 2000). It has been also suggested that
rabbits infected with polyoma virus produce lupus-like autoantibodies to DNA (Flaegstad
et aI. , 1988). With the exception of lupus-like autoantibodies, no connective tissue
disease autoantibodies could be induced by experimental infection.
Autoantibodies to Centrosomes in Infection. Similar to other connective tissue disease
autoantibodies, autoantibodies to the centrosome have been also correlated with human
infections with EBV, HIV and mycoplasma (Auer-Grumbach and Achleitner, 1994;
Cimolai et aI. , 1994; Gentric et aI., 1991; Huidbuchel et aI. , 1991; Lind et aI., 1988;
Moteki et aI. , 1991). We have shown that autoantibodies to centrosome proteins can be
induced through experimental exposure of mice to a mycoplasma. With time, the
centrosome-specific reactivity expands to include autoreactivity to endoplasmic-
reticulum autoantigens. These findings show that mycoplasmas induce complex
autoantibodies in mice and suggest they may be cofactors in the pathogenesis of human
autoimmune diseases.
CHAPTER II
CENTROSOME PROTEINS: A MAJOR CLASS OF AUTOANTIGENS
IN SCLERODERM
A. Abstract
Autoantibodies to intracellular antigens are a hallmark of autoimmune diseases, although
their role in disease pathogenesis is unclear. Centrosomes are organelles involved in the
organization of the mitotic spindle , and they are targets of autoantibodies in systemic
sclerosis (SSc). We used recombinant centrosome autoantigens , centrosome-specific
antibodies , and immunoassays to demonstrate that a significant proportion of SSc patients
exhibited centrosome reactivity. Two centrosome proteins cloned in our laboratory were
used to screen 129 SSc sera by Western blotting. The same sera were screened by
immunofluorescence using centrosome-specific antibodies to distinguish centrosomes
from the nuclear speckles commonly stained by SSc sera. Using these criteria, 42.6% of
SSc patients were autoreactive to centro somes, a larger percentage than reacted with all
known SSc autoantigens. Most centrosome-positive sera reacted with both centrosome
proteins , and half were negative for other routinely assayed SSc autoantibodies. By these
criteria, we have identified a novel class of SSc autoreactivity. Only a small percentage of
normal individuals and patients with other connective tissue diseases had centrosome
reactivity. These results demonstrate that centrosome autoantibodies are a major
component of autoreactivity in SSc and thus have potential in disease diagnosis.
Centrosome autoantigens may be useful in studying the development of autoantibodies
and chronic inflamation in SSc and perhaps other autoimmune diseases.
B. Introduction
Systemic sclerosis (SSc) is an autoimmune disease characterized by microvascular
lesions, lymphocytic infiltrates and fibrosis of the skin and visceral organs (LeRoy, 1996;
Mitchell et aI., 1997; White, 1996). The majority of patients produce autoantibodies to
proteins of intracellular organelles. While many of these autoantibodies are shared among
other autoimmune diseases, some are known to be specific for SSc and thus serve as
useful immunological markers in disease diagnosis (Gal perin et aI., 1996). The
intracellular targets of SSe autoantibodies are found mainly in the nucleus (Okano, 1996).
Among these are antibodies to DNA topoisomerase I and to centromere proteins on
kinetochores of chromosomes. While both classes of autoantibodies are good indicators
of disease, only anti-topoisomerase autoantibodies are associated exclusively with SSc
and not found in other autoimmune diseases (Okano, 1996; Vazquez-Abad and Rothfield
1995). Another organelle that is a target of autoantibodies in SSe is the centrosome
(Tuffanelli et aI. , 1983).
Centrosomes are intracellular organelles that nucleate microtubules and organize the
bipolar mitotic spindle during cell division , although little is known of the molecular
components involved in these functions (Dictenberg et aI. , 1998; Doxsey et aI., 1994;
Kellogg et aI. , 1994). To identify centrosome components , we previously utilzed anti-
centrosome autoantibodies from patients with SSc to screen cDNA expression libraries
(Doxsey et aI. , 1994). In this way, we identified two centrosome proteins that we named
pericentrin and CP140 (centrosome protein of 140 kDa) (Doxsey et aI. , 1994). Using
recombinant proteins from these cloned centrosome antigens and antibodies specific for
these molecules , we investigated the prevalence of centrosome autoreactivity by
immunofluorescence (IF) and Western blotting.
Previous reports indicated that the prevalence of centrosome-specific autoantibodies in
SSc was quite low (4-6%) compared to the prevalence of antinuclear antibodies (50-
90% )(Tuffanell et aI. , 1983). We believe that the reported centrosome reactivity was
underestimated due to assay insensitivity and the small patient cohort examined. In this
study, we re-examine the prevalence of anti-centrosome antibodies in scleroderma using
two novel assays for centrosome autoantigen detection. The first involves the use of two
distinct recombinant centrosome proteins for probing patient sera by the Western blot
technique. The second is an IF assay that employs two unique modifications: the use of a
centrosome-specific antibody to identify unequivocally centrosome reactivity of
autoimmune sera in double-label IF reactions and a detergent prepermeabilization step
that removes soluble cytoplasmic staining that often obscures the centrosome signal. As a
consequence of these methodological optimizations, we show that autoreactivity to the
centrosome is more prevalent in SSc than reactivities to all other individual SSc
autoantigens.
C. Results
Analysis of Centrosome Reactivity by Immunofluorescence. The prevalence of
centrosome autoreactivity was examined in 129 SSc patients by imunofluorescence on
human cultured cells (HepG2) using an antibody to pericentrin as a marker for the
in C). Other SSc sera gave a complex pattern of multiple dots in and around the nucleus.
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centrosome (Doxsey et aI., 1994). This antibody gave the characteristic centrosome
pattern of one or two small fluorescent dots adjacent to or superimposed on the nucleus
(Figs. IA and D). A proportion of the SSc sera gave this same pattern and did not
appreciably stain the nucleus or other cellular structures (Fig. IB , A and B superimposed
In these sera, centrosome reactivity was scored as positive when the signal from patient
sera (Fig. IE) was coincident with that of the pericentrin label (Fig. ID), giving a yellow
color when the signals were superimposed (Fig. 1 F). Using these criteria, 41.1 % of sera
from SSc patients had anti-centrosome autoantibodies.
Analysis of Centrosome Reactivity by Immunoblotting. An independent biochemical
assay was used to analyze centrosome reactivity in the same cohort of SSc patients. This
approach also enabled us to determine the molecular specificity of the reactivity
identified by immunofluorescence. In this assay, recombinant pericentrin and CP140
were probed with SSc sera by Western blotting (Fig. 2A and B). Signals generated by the
autoimmune sera used to identify these proteins in the original screen are shown in lanes
2 and 3 and they serve as positive controls for the test sera (Doxsey et aI. , 1994). Normal
human sera are shown in lanes 1 , 14 and 24 and serve as negative controls in this assay.
An example of a test serum that did not react with either of the two centrosome proteins
is shown in lane 19. Examples of positive test sera with variable levels of reactivity are
shown in lanes 7- , 21 and 23. The results of the Western blot assay demonstrate that
autoreactivity to CP140 and pericentrin was 26% and 27% respectively (Fig. 3 , columns
A and B). The cumulative reactivity against both centrosome proteins was 30.2% (Fig. 3
colum C). For comparison, the results from the morphological assay are shown in Fig. 3
colum d. The cumulative reactivity of both techniques was 42.6% (Fig. 3 , colum E).
Nearly all of the sera positive by the biochemical assay were also positive by
imunofluorescence (not shown).
Comparison of Centrosome Autoreactivity with Other SSe Autoantigens. We next
determined whether the centrosome autoreactive sera also had reactivity to other
autoantigens. Fort-nine percent of these patients had additional reactivity to one or more
of the following autoantigens: topoisomerase I , centromeres , double-stranded DNA
small nuclear ribonucleoproteins , Sm, La, and Ro (Galperin et aI. , 1996; Okano, 1996;
Vazquez-Abad and Rothfield, 1995; Vazquez-Abad et aI. , 1994). Interestingly, 51% of
patients with centrosome reactivity did not react with any of the other routinely assayed
autoantigens. This group of patients with autoreactivity to centrosome proteins
establishes a previously unidentified category of autoreactivity in SSc that could have
diagnostic potential.
Centrosome Autoreactivity, Clinical Forms of the Disease, and Clinical Disease
Features. Of the patients autoreactive to centrosome proteins, we found no significant
difference between patients with different clinical forms of the disease (Calcinosis
Raynaud s phenomenon, Esophageal dysmotility, S clerodactily, Telangiectasias
CREST , limited or proximal scleroderma; 0.24928 , 0.882?P?0.005). We also found
no statistically significant difference among patients with centrosome reactivity that had
lung involvement , 0.82?P?0. 005), heart involvement 
73?P?0. 005), or involvement of the gastrointestinal tract , 0.48?P?0.005); this
cohort of patients was not uniformly characterized for renal involvement. No differences
were noted when using data from immunofluorescence or immunoblotting or both
combined.
Disease specificity of centrosome auto reactivity. To determine whether centrosome
reactivity was specific for SSc, we screened sera from 73 normal individuals and 71
patients with other autoimmune diseases (Fig. 4). Of the 73 normal individuals
investigated, only 2.7% were positive for anti-centrosome autoantibodies, a value
significantly lower than the prevalence of centrosome autoreactivity in SSc patients
(Z=4.6598 , P-:0.00001) and not significantly different from the 2% prevalence of ANA
previously reported in the normal population (Z=0.4516, P?0.3264). Of the sera from 71
patients with other autoimmune diseases (see Chapter II), 11.1% had anti-centrosome
autoantibodies. These included patients with SLE, rheumatoid arthritis and Sjogren s
syndrome. This result demonstrates that centrosome autoreactivity, while prevalent in
SSc, is also found in some other autoimmune diseases , albeit at significantly lower
frequencies (Z=2.793 , p-cO.Ol).
D. Discussion
High Prevalence of Centrosome Autoantibodies in SSe. A major fmding of this study
is that centrosome autoreactivity in SSc is higher than autoreactivity to all other known
SSc autoantigens reported in the literature. This conclusion is based on the analysis of
129 patients with SSc, 71 patients with other autoimmune diseases, and 73 healthy
individuals. The proportion of centrosome-reactive sera in this analysis (30-43%) was
significantly higher than reported previously (4-6%) (Tuffanell et aI. , 1983). This is
likely due to three technical improvements: the development of a biochemical assay for
centrosome autoantigens , the use of centrosome-specific antibodies, and a pre extraction
method for the IF assay to distinguish unambiguously centrosomes from nuclear speckles
commonly stained by SSc sera.
The high level of centrosome autoantibodies detected in SSc sera is likely an
underestimate since the truncated recombinant centrosome proteins used in the
biochemical analysis were probably mIssmg additional immunoreactive epitopes.
Furthermore, additional centrosome autoantigens are known to exist since they were
identified together with pericentrin and CP140 in the original screen (S. Doxsey,
unpublished observations), but they have not yet been characterized or tested for
recognition by SSc sera (Doxsey et aI. , 1994). Judging by the imperfect overlap of
immune responses to pericentrin and CP140 (Fig. 3), the untested centrosome proteins
will likely increase the total centrosome reactivity found in SSc above the levels reported
here.
Centrosome Autoantibodies as a New Diagnostic Tool for Scleroderma. A second
major finding presented in this study is the exclusive occurrence of centrosome
autoantibodies in half the SSc patients with centrosome autoreactivity. This observation
demonstrates that centrosome autoantibodies define a novel subset of patients that lack
reactivity to the autoantigens that are commonly used today to aid in clinical diagnosis
(ACA and anti-topoisomerase antibodies). It will be interesting to determine how
centrosome autoreactivity compares with reactivity to RNA polymerases, for which
assays are not routinely employed in clinical diagnosis and which were not screened in
this study (Okano, 1996).
The calculated sensitivity ofthe diagnostic test for centrosome autoantigens in SSc (0.30)
is higher than that for ACA and anti-topoisomerase antibodies (0.26 and 0.
respectively) (Okano , 1996; Vazquez-Abad and Rothfield, 1995).
Although encountered in other connective tissue diseases, the high disease specificity of
centrosome autoreactivity (0.9726) and its high positive predictive value for SSc (0.95)
indicate that this assay wil provide an effective new diagnostic tool for scleroderma.
When used together with assays for ACA and anti-topoisomerase, tests for anti-
centrosome reactivity could add significant sensitivity to disease diagnosis.
Possible Mechanism for Generating Multimolecular Autoreactivity to Centrosornes.
The loss of tolerance to intracellular proteins in systemic autoimmune diseases such as
scleroderma is not understood, although several mechanisms have been proposed. Among
them is the hypothesis that autoreactivity to multiple protein components of an
intracellular organelle may be the result of a loss of tolerance to an initiating self-epitope
(Bockenstedt et aI. , 1995; James et aI. , 1995; Topfer et aI. , 1995). This epitope could be
targeted by the immune system by virtue of sequence homology to a non-self antigen
(e.g. a virus), a mechanism called molecular mimicry. Alternatively, this epitope could be
cryptic and not exposed when self-proteins are presented to T and B cells in a
tolerogenic mode (Bockenstedt et aI. , 1995). Cryptic epitopes could be exposed as a
consequence of pathologic processes , such as vascular spasm in scleroderma. Ischemia
reperfusion, and the release of oxygen radicals that follow vascular spasm could cleave
intracellular proteins and reveal cryptic epitopes (Cascio la-Rosen et aI. , 1997).
Regardless of the mechanism, initial loss of tolerance to one epitope could be followed
by sequential loss of tolerance to multiple epitopes of the same protein , a mechanism
called intramolecular epitope spreading (Topfer et aI., 1995). Results from this
investigation and another study show that autoantibodies to multiple centrosome
components are present together in the same sera (Figs. 2 and 3), consistent with
intermolecular spreading (Mack et aI. , 1998). More work wil be required to identify self-
epitopes that initiate the autoimmune response to centrosome proteins during chronic
inflammation in SSc and other autoimmune diseases. In addition, the mechanism by
which exclusive reactivity to one class of autoantigens is accomplished (ex. Centrosomes
and not centromeres; Figs. lA-C) is also an important remaining question.
Figure 1. Immunofluorescence images of cells co-labeled with pericentrin and SSe
sera. (A) Pericentrin staining of HepG2 cells using a secondary fluorescein anti-rabbit
IgG (green). (B) Autoimmune sera on the same cell using Cy3 anti-human IgG (orange).
(C) An overlay of both channels showing coincidence of centrosome and autoantibody
staining (yellow), together with DNA staining to visualize nucleus (blue). (D) Pericentrin
staining as in A. (E) Autoimmune sera on the same cell showing numerous "nuclear
speckles" present in most SSc sera (F). Overlay of both chanels reveals centrosome
reactivity (yellow).

Figure 2. Immunoblots of recombinant centrosome proteins using SSe sera.
Recombinant pericentrin (A) and CP140 (B) were partially purified, separated on
acrylamide gels, and transferred to Immobilon membranes. They were blotted with
autoimmune sera or sera from normal individuals (controls). HRP-conjugated secondary
antibodies raised against human IgG were used to detect primary autoantibodies.
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Figure 3. Immunoreactivity to CP140 and pericentrin in SSe. The percentage of
patients positive for reactivity to CP140 (column A) or pericentrin (column B) by
Western blot was determined and plotted individually or as a cumulative percentage
(column C). Total centrosome reactivity of SSc patients by immunofluorescence is
depicted in column D. Cumulative reactivity from both techniques is shown in column E.
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Using the chi-square test as a test for independence , the results of the biochemical
analysis show a strong dependence compared with the morphological results(P':O. OOOI).
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Figure 4. Disease specificity of centrosome auto reactivity. Centrosome autoantibodies
were found in 30-43% of SSc sera. In other connective tissue diseases, centrosome
reactivity was 11 %. Centrosome autoreactivity was present in only 2.7 % of the normal
population, a value similar to that described for other autoantigens.
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CHAPTER 
SCLERODERMA-LIKE FEATURES IN MICE: MYCOPLASMA INDUCES
CENTROSOME AUTOREACTIVITY THAT SPREADS OTHER
ORGANELLES
A. Abstract
Development of autoantibodies to intracellular molecules is a universal featue 
autoimmune diseases and parallels the onset of chronic inflammatory pathology. 
recently demonstrated that the major target of autoantibodies in scleroderma are
centro somes, organelles that orchestrate mitotic spindle assembly in dividing cells. Here
we demonstrate that this novel class of autoantibodies can be induced in mice following
exposure to mycoplasma. Unlike other experimentally induced autoantibodies
autoreactivity was initially specific for centro somes, later spread to include other
intracellular targets and in the process class switched from IgM to IgG isotypes.
Antibiotic treatment of mice prevented centrosome autoantibody development. Our
findings demonstrate that mycoplasma induces complex autoantibody responses in mice
providing support for the idea that these microorganisms contribute to autoantibody
development and pathogenesis in human autoimmune diseases and suggesting that they
may represent novel therapeutic targets.
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B. Introduction
Development of autoantibodies to a wide variety of organelles and proteins is an early
featue of most human autoimmune diseases (Hiepe et aI. , 2000; Sontheimer et aI. , 1992;
Tan et aI. , 1988). However, little is known about the events that initiate autoantibody
III
development or the mechanisms that sustain their production. Even less is known about
1Ci
the mechanisms that control targeting of specific antigens and organelles during humoral
autoimmune responses.
I,;
Infectious agents have been implicated in the development of autoantibodies in human
II"
diseases (Bach et aI. , 1998; Walton, 1968). Infections exacerbate pathological symptoms
of many autoimmune diseases and can induce chronic autoimmune syndromes in both
humans and animal models of human disease (Cole et aI. , 1975; Cole et aI., 1976;
Harwick et aI., 1973; Hiepe et aI. , 2000; Hughes and Keat, 1994). Autoantibodies
characteristic of some systemic autoimmune diseases correlate with infection (Newkirk
2002; Rekvig et aI. , 1997; Rose, 2001) and in some cases can be induced by experimental
infection with viruses , bacteria or parasites (Flaegstad et aI. , 1988; Olding et aI. , 1976;
Sangster et aI. , 2000).
Several mechanisms have been proposed to link infection and autoantibody development.
In the molecular mimicry model , autoantibodies are induced upon infection by peptide
antigens on pathogens that share homology to self-peptides (Bachmaier et aI. , 1999; Ray
et aI. , 1996). II! a broader sense, structural similarity of pathogen and self components can
account for the stimulation of common receptor(s) to activate autoreactive B
lymphocytes. For example , the same Toll-like receptors can be triggered by structurally
related pathogen and self components and initiate autoantibody production through B cell
receptor-independent pathways (Vinuesa and Goodnow, 2002). The autoantibody
response can be specific rather than polyclonal if low doses of stimulatory molecules or
immune complexes co-engage the appropriate Toll-like and antigen receptors (Coutinho
and Moller, 1974; Leadbetter et aI. , 2002). These pathways have been implicated in
triggering autoantibody production in response to non-self and self molecules including
proteins , polysaccharides, lipopolysaccharides, lipoprotein and nucleic acid (Hacker et
aI. , 2000; Kawai et aI. , 1999; Li et aI., 2001; Lien et aI. , 1999).
There is currently little evidence to support a role for infectious agents in the
pathogenesis or autoantibody development in scleroderma, a human systemic
autoimmune disease characterized by chronic inflammation of the skin and visceral
organs(Gililand, 1998). Self epitopes recognized by autoantibodies in scleroderma
patient sera share sequence homology to epitopes on retrovirus and herpesvirus antigens
(Jimenez et aI. , 1995; Lunardi et aI. , 2000). However, these cross-reactive viral epitopes
have not been shown to act as dominant targets of immune responses during viral
infection nor have they been shown to initiate an immune response to self antigens during
scleroderma pathogenesis. One limitation to this type of analysis is the lack of an
experimental system to test whether infectious agents can directly initiate autoantibody
responses to scleroderma autoantigens.
Centrosomes are inconspicuous organelles approximately 1 mm in diameter that form
microtubule arrays in interphase cells for controllng cell shape and polarity, and they
organize microtubule spindles in mitotic cells to ensure proper chromosome segregation
(Doxsey, 2001). We recently discovered that centro somes are the major autoantibody
target in scleroderma (Fauci, 2001-2002; Gavanescu et aI. , 1999). The high prevalence of
centrosome autoreactivity was somewhat surrising given the low level of centrosome
autoreactivity previously reported in autoimune diseases(Kellogg et aI., 1994).
Unambiguous identification of centro somes was achieved by using more sensitive and
specific centrosome assays and demonstrated that these tiny organelles have important
diagnostic potential in scleroderma.
In this study, we show that mycoplasma infection is associated with centrosome
autoantibodies and that isolated mycoplasma can directly trigger centrosome-specific
autoantibodies when introduced into naive mice. Centrosome autoreactivity expands with
time to include other intracellular organelles and is prevented by treatment with
antibiotics. These results provide the first evidence for a scleroderma-like autoantibody
response that is initiated by the loss of tolerance to centrosome auto antigens and occurs
as a consequence of infection.
C. Results
We recently showed that centro somes are a previously unappreciated autoantibody target
in human scleroderma (Gavanescu et aI., 1999). Centrosome autoantibodies are more
prevalent than all other autoantibodies in this disease making them an important
diagnostic indicator and suggesting that they may play role in disease
pathogenesis(Fauci, 2001-2002). To understand more about centrosome autoantibody
development, we examined the phenomenon in a murine experimental system. Using
morphological and biochemical assays to detect centrosomes and centrosome
auto antigens (Doxsey et aI., 1994; Gavanescu et aI., 1999), we observed sporadic
centrosome autoreactivity in several mouse colonies. Up to 35% of animals in some
colonies had centrosome autoantibodies while other colonies had undetectable levels of
centrosome autoreactivity (Table I).
The sporadic occurence of centrosome autoreactivity in mice was consistent with a
model in which autoantibodies developed by transmission of an infectious agent. To test
this hypothesis, we asked whether autoantibody reactivity could be initiated through
contact with infected animals. We unexpectedly found that naive mice housed with sero-
positive but not sero-negative mice rapidly developed a specific autoantibody response to
centrosomes and centrosome antigens (Fig.5).
I .
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Characteristics Infectious Agent that Induces Anti-Centrosome
Autoantibodies. To isolate the putative infectious agent responsible for centrosome
autoantibody development, we prepared suspensionhomogenates from mouse spleens
and used them to inoculate cultued mamalian cells. Plaques formed in cell monolayers
inoculated with homogenates from mice with centrosome autoantibodies , but not from
centrosome autoantibody-negative anmals (data not shown). The infectious agent was
g/cm , Fig.6c).
'11o11
plaque-purified (Fig 6a-b) , and then banded on renografin density gradients (1. 19- 1.20
observed with spleen homogenates and were atypical in many ways. Plaque formation
hltl
it'il
,.tulPlaques induced by the isolated infectious agent were indistinguishable from those
epithelial cells from human, monkey and mouse). Infection of cultured cells occured
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was unusually prolonged (7- 10 days post-infection compared to most viruses, 1-4 days)
and was consistently observed in a wide range of host cells (fibroblasts, lymphocytes and
without significant cell lysis (Fig. 6h), except in agar plaque assays where cells lost could
out most viruses as infectious agents. The infectious agent appeared to be a membrane-
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not be replaced by the ingrowth of the surounding monolayer. Several antibiotics
prevented plaque formation (doxicyclin, ciprofloxacin, actinomycin D , Fig. , b) ruling
bound, DNA-containing paricle. It was unable to induce plaque formation when treated
with organc solvents or nonionic detergents. Antibodies generated against renografin
fractions in mice labeled DNA-containing subcellular paricles at the margins of plaques
when visualized by immunofluorescence microscopy (Fig. 6d-g). Electron microscopic
examination of plaques (Fig.8c) and pellets of peak gradient fractions (Fig.8d) revealed
phenotypically homogeneous structures 0.45 m in diameter that lacked cell walls and
were closely apposed to the plasma membrane of host cells (Barile and Razin, 1979).
Taken together, these featues suggested that the agent was a mycoplasma.
Identification of the Infectious Agent as Mycoplasma. 
We used several approaches to
confirm that the infectious agent was a mycoplasma. We obtained a monoclonal antibody
specific for Mycoplasma hyorhinis variable lipoprotein (Vip) (Rosengarten and Wise
1990) and used immunofluorescence microscopy to show that it labeled the margins of
plaques containing our infectious agent (compare Fig. 8a-b and Fig. 6d-g). A second
poly clonal anti-mycoplasma antibody also labeled small dense particles from our
renografin fractions that co-labeled with the antibody generated by mice infected with
renografin fractions. In another approach, we obtained Mycoplasma hyorhinis from a
commercial source and demonstrated that it formed plaques with similar morphology and
kinetics to those observed following inoculation with renografin fractions. The identity of
the infectious agent as mycoplasma was definitively determined by DNA sequence
analysis.
DNA was isolated from peak renografin gradient fractions , restriction-enzme digested
cloned and sequenced. Sequences from most clones (74%, n=34) exhibited a high degree
of homology to Mycoplasma genes including variable lipoprotein (vip), 16S/23S rRNA
intergenic spacer, pyruvate dehydrogenase, aminoacid permease and methylase (Fig. 9a-
, Table II); the remammg clones had no significant homology to NCBI database
sequences. Additional sequences were obtained by PCR analysis .of DNA from our
renografin-fractionated material. Several genes were amplified and again, all were most
homologous to mycoplasma sequences including the 16S rRNA gene, the putative
transcription elongation factor (tuf) and triosophosphate isomerase (tpi Table II).
Sequences obtained both by random cloning and PCR analysis shared strongest
homology with the porcine pathogen Mycoplasma hyorhinis. Because mycoplasmas are
known contaminants of tissue culture cells, we performed additional tests to demonstrate
that our fractions were derived from mouse material. We took precautions to specifically
use mycoplasma-free cell lines available from ATCC and confrmed that they were
mycoplasma-free by PCR using highly sensitive commercial primers (Stratagene) or
those produced in our own laboratory (see Materials and Methods). Importantly, we
showed that mycoplasma sequences could be amplified directly from spleens and lungs
of mice that had spontaneously produced centrosome autoantibodies (above) but had
never come in contact with tissue culture materials.
Mycoplasma Induces Centrosome Autoantibodies in Naive Mice. To demonstrate that
mycoplasma was the causative agent of autoantibody production in mice, we delivered
plaque-purified, gradient banded mycoplasma fractions to naive wild type mice and
assayed for centrosome autoreactivity. Intranasal delivery consistently induced
autoantibody production in over half the mice (Fig. 10 a- , Table III). Oral delivery was
also effective while intraperitoneal or intravenous injection induced no autoantibodies
demonstrating that the mode or route of delivery was important for autoantibody
production (Fig. 11). The effcacy of intranasal delivery of mycoplasma suggested that
autoantibody development may require an acute infection, perhaps within mucosal
tissues. To test for mycoplasma infection, we examined sera from intranasally infected
and control mice for the presence of anti-mycoplasma antibodies by immunofluorescence
staining of mycoplasma particles affixed to coverglass (above). All anmals that produced
centrosome autoantibodies following delivery of mycoplasma had detectable anti-
mycoplasma antibodies in their sera. In contrast, anmals that received control inoculum
showed no detectable signs of anti-mycoplasma antibody production. These and other
results (below) suggested that infection by mycoplasma is required to induce centrosome
autoantibody production.
Mycoplasma-Induced Centrosome Autoantibodies Can Be Prevented by Antibiotic
Treatment. The ability to induce centrosome autoantibody production by infection with
mycoplasma offered a unique opportnity to test whether autoreactivity could be
inhibited by targeting mycoplasma with antibiotics. As expected, mice that received
solution without the antibiotic ciprofloxacin mounted a strong autoantibody response
(Fig. 12). However, pretreatment of mice with ciprofloxacin prior to mycoplasma
infection inhibited autoantibody production ( P=O.0013 Fig. 12). Centrosome
autoantibodies were undetectable at all times examined (from 0 to 6 weeks post-
infection) and were indistinguishable from uninected mice. A low percentage of
infected, antibiotic-treated mice developed strong autoreactivity ( 0%). Although we do
not have an explanation for this result, it may be due to ineffective delivery of the
antibiotic, incomplete bacteriostatic activity of the antibiotic in some mice, or other
reasons.
The Centrosome Autoantibody Response Involves Isotype Switching and Amplifies
to Include Additional Intracellular Targets. A more detailed analysis of centrosome
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IgG isotype (Fig. 1 Ot). Importantly, anti-centrosome IgMs were detectable by IgM-
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specific secondary antibodies in naive wild-type mice, and their titers do not increase
following mycoplasma infection (Fig. l0e). This suggests that the self-reactive B
lymphocytes that contribute centrosome-reactive IgMs to the natural antibody repertoire
of unimmunized mice, may respond to infection by class switching to high titer IgGs.
The centrosome autoantibodies are of the IgG 1 and IgG2b subclasses and appear as early
as 2-3 weeks post-infection in some animals and are well established by 6-8 weeks in all
animals. These anti-centrosome IgGs remain the only detectable autoantibody specificity
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for at least 8 weeks post-infection (Fig lOa-d).
A unique feature of the murne autoantibodies produced by mycoplasma infection was
their exclusive centrosome-specificity. This raised the hypothesis that centrosomes may
initiate an autoantibody response that subsequently spreads to include reactivity to other
intracellular organelles. This phenomenon, known as antigenic spreading, has been
implicated in the generation of complex multi-target autoantibody responses in
autoimmune diseases (Craft and Fatenejad, 1997). To address this issue, we examined
mice at later times after mycoplasma infection to determine whether additional
1 .
autoantibodies were generated. Beginning at approximately 12 weeks post-infection
autoantibodies to another intracellular structue were detected in infected mIce.
Immunofluorescence co-localization of mycoplasma-induced autoantibodies with
antibodies to calnexin (Fig. 13 a-c) and to the Binding protein of the endoplasmic
reticulum (Bip, data not shown) (Linnik and Herscovitz, 1998; Nelson et aI. , 1998),
demonstrated that this strcture was the endoplasmic reticulum (ER). Autoantibodies 
the ER developed specifically in infected mice, they had lower titer than anti-centrosome
autoantibodies and they were oflgM isotype only (Fig. 13d-e). These results demonstrate
that mice elicit complex autoantibody responses following mycoplasma infection.
D. Discussion
These experiments show that mycoplasma infection causes the development of
scleroderma-like anti-centrosome autoantibodies in mice. They represent a first
demonstration of a complex autoantibody response initiated by centrosome autoantigens
which spreads to include additional auto antigens and is treatable by the antibiotics that
eradicate the bacterial infection. These results also imply that the initial loss of tolerance
to centrosome antigens precedes the development of the more complex autoantibody
response to numerous autoantigens, which occurs in scleroderma.
One aspect of autoantibody development in mycoplasma-infected mice unique from other
experimental systems is that the initiating target antigens are exclusively centrosomai.
This is in contrast to other studies , which describe infection-induced autoantibodies with
multiple specificities characteristic of systemic lupus erythematosus(Flaegstad et aI.
1988; Olding et aI. , 1976; Sangster et aI. , 2000). These studies may either describe a
polyclonal B cell activation or not distinguish an initiating autoantigen.
The initiation of autoreactivity in scleroderma by centrosome antigens is supported by a
prospective study of autoantibody development in a large cohort of individuals at risk for
occupational scleroderma. A subset of these individuals developed Raynaud' s syndrome
a prodromal scleroderma featue, and progressed to suspected, then certain, scleroderma.
At the earliest stages of disease, autoantibodies to mitotic spindles were the only detected
specificities (Conrad and Mehlhorn, 2000). Prior to this prospective study, patients with
Raynaud syndrome or scleroderma having only autoantibodies to centrosomes have been
described in a number of reports (Doxsey et aI. , 1994; Gentric et aI. , 1990; Mack et aI.
1998; Moteki et aI. , 1991; Osborn et aI. , 1982). It is conceivable that autoantibodies to
mitotic spindles or centro somes are masked at later disease stages by the development of
additional autoantibody specificities (Gavanescu et aI. , 1999).
Autoantibodies to nuclear antigens may be spontaneously generated in normal mice by
altering the signalling theshold of B cells. B cells from mice transgenic for the human
activating receptor CDI9, which have a lowered signalling threshold, develop only
autoantibodies to the centriole, which is the centro somal core , when the trans gene is
expressed at low levels. Higher levels of trans gene expression trigger the development of
a homogeneous nuclear staining pattern in addition to centriolar (Sato et aI. , 2000). These
data imply that autoreactive centrosome-specific B cells have less stringent activation
requirements compared to other autoreactive B cells and 
are activated first during
scleroderma-like autoantibody responses.
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Individuals with M. pneumoniae infection frequently develop both recurring and rare
filaments and mitotic spindle (Cassell et aI. , 2001-2002). The oligocIonal IgM
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the experiments of this report are very similar to the IgM autoantibodies specific for the I
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autoantibody responses to endoplasmic reticulum antigens that result upon infection in
antigen of red blood cells frequently induced by Mycoplasma pneumoniae (Cassell et aI. fll
2001-2002). Autoantibodies to mitotic spindles, centro somes or centrioles are very rare 
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Huidbuchel et aI. , 1991; Lind et aI. , 1988; Moteki et aI. , 1991). Although anecdotal, these
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association with infection, in patients infected with Mycoplasma pneumoniae, EBV or
HIV (Auer-Grumbach and Achleitner, 1994; Cimolai et aI. , 1994; Gentric et aI., 1991;
correlations support the results of our experiments.
The mechanism by which mycoplasma infections initiate immune responses that
ultimately result in autoantibody production is currently unkown. Mycoplasmas present
a variety of structures capable to engage both innate and adaptive components of the
immune system. Mycoplasma superantigens have been described and may account for
polyclonal activation of autoreactive B and T cells with anti-centrosome and anti-
specificities. The mycoplasma macrophage-activating lipopeptide (MALP) may be able
to stimulate B lymphocytes that also express Toll-like 2 receptors (Lien et aI., 1999;
Seya and Matsumoto, 2002; Takeuchi et aI., 2000). Toll-like receptors can initiate
polyclonal autoantibody responses that may include anti-centrosome and anti-
specificities. dual activation of Toll-like and specificHowever receptors
immunoglobulin receptors has been recently demonstrated to initiate specific
autoantibody responses and is most likely to account for the oligoclonal anti -centrosome
and anti-ER autoantibodies described in this work (Leadbetter et aI. , 2002).
Autoantibody responses initiated by centrosome antigens may be amplified by the
recruitment of additional specificities. Such amplification results when the response to
the initiating epitope expands to encompass epitopes within the same or within adjacent
molecules; this process, defined as epitope spreading has been observed frequently
following peptide immunization (Bockenstedt et aI. , 1995; Craft and Fatenejad, 1997). As
the expansion of the response to immunodominant epitopes progresses, isotype shifts
result, from IgM to other isotypes (Scofield et aI. , 1996). IgM autoantibodies may be
initially recruited into the response from the natural antibody repertoire. Autoreactive
IgM of the natural antibody repertoire have a dual role in the unimmunized host, of
providing protection from bacteria and clearing altered self-antigens that result from
lipoprotein oxidation or cellular apoptosis (Briles et aI., 1982; Shaw et aI., 2000).
Similarly, anti-centrosome IgM may be part of the natural antibody repertoire of normal
mice and have the role to provide protection against mycoplasmas, while exacerbations
of the numbers of infectious paricles during acute mycoplasma infections may trigger
class-switching to anti-centrosome IgG. As the response to the initiating epitope
progresses to IgG isotype, epitope spreading may involve additional epitopes on ER
antigens by recruiting new autoantibody specificities of IgM isotypes.
Lastly, initiation of scleroderma-like autoimmune responses by bacterial pathogens
suggest that antibiotic treatment at early stages of scleroderma may have an ameliorative
effect. Intriguing clinical remissions of scleroderma with antibiotics effective on
mycoplasmas have already been reported (Le et aI. , 1998) (Over and Bucknall, 1998).
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Table I. Prevalence of Anti-Centrosome Autoantibodies in Mouse Colonies
Method Colony Proportion centrosome
autoantibody- positive
Immunoblotting to recombinant 0/17 (0%)
centrosome protein pericentrin
0/5 (0%)
1/6 (16%)
5/20 (25%)
Immunofluorescence to centrosome 55/154 (35%)
co-labeled with marker antibody to
pericentrin 1/6 (16%)
Academic and commercial mouse colonies listed in Materials and Methods
Fig 5. Induction of centrosome autoantibody development. 
Autoantibodies can be
transmitted to naive mice housed with autoantibody-positive mice. Immunoblots of
recombinant pericentrin (a) or centriolin (clone name CP140 , b), using ten-fold serially
blots a, b), and when placed in contact with an anti-centrosome antibody-positive mouse
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dil uted sera from two mice that were naive at the initiation of the experiment (lanes 1-
18 blots a, b) 2 weeks after being housed in contact with sero-positive mice. The result is
Ilij,
lii
1:1:,,
;"11
'ot
(lanes 7- 12 blots a, b), but develop autoantibodies to pericentrin and centriolin (lanes 13-
representative of 2 experiments.
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Fig.6. Isolation and characterization of a plaque-forming infectious agent. Infected
inoculi form plaques in a concentration-dependent manner when serially diluted and
inoculated on cultured Vero cell monolayers (a) while no plaques are seen in cells
inoculated with culture media alone (b). Banding and enrichment of infectious agent in
renografin gradients. Titers are determined by plaque assay (diamonds
, 10glO titer in
plaque-forming units
, p.
). Refractive index (squares) of renografm gradient fractions
(c). Antibodies developed by mice immunized with the infectious agent detect cell-
associated antigen at the margin of a plaque( d). Dapi-staining nuclei of cell monolayer
surrounding a plaque(e). Spherical, pariculate antigenic structures within infected cells
(f) co-localize with DNA-containing particles labeled by dapi (g). Titer of infectious
agent increases and plateaus in infected cultues at similar rates irrespective of whether
high or low multiplicity of infection (m.oj. , same number of p.f.u for squares=10 cells
infected /well and diamonds=10
4 cells infected/well) (h).
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Fig. 7. Infectious agent sensitivity to antibiotics. The munne infectious agent is
sensitive to treatment with bactericidal antibiotics (doxicyclin and ciprofloxacin, a).
Plaque formation is abolished in antibiotic-treated, but not in untreated cultures;
uninfected mono layers do not develop plaques (assay sensitivity, 10 plaque-forming
actinomycin D , an antibiotic that inhibits DNA-dependent RNA synthesis (b). Infectious
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units/ml). The growth of the murine infectious agent is inhibited by treatment with
agent titers increase 100 fold over 24 hours of infection (monolayer of293T cells, 8), but
no growth is detected when infected cultures are treated with actinomycin D ("). Herpes
simplex virus I is used as a positive control , showing plaque-formation in the absence (
but not in the presence(X) of actinomycin D. Sindbis virus growth has the same kinetics
independent of the presence(.) or absence(+) of actinomycin D. Act.D was added 6
hours post-infection for the rapidly growing Sindbis virus and 12 hours post infection for
the murine infectious agent and the herpes virus; addition of act. D at 12h defines the
starting point of the time course. Assay detects 10 pfu/mi.
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Fig. 8. Identification of the plaque-forming infectious agent as a mycoplasma using a
monoclonal antibody specific for a unique Mycoplasma hyorhinis surface antigen (a).
Nuclei of Vero cells surrounding the plaque are stained with dapi (b). Electron
microscopy reveals that the infectious agent associated with plaques (c) and present in
peak gradient fractions (d) has a morphology consistent with that of a mycoplasma.
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Table II. Summary of Seauences of the Murine Mvconlasma Isolate
Gene name (symbol) Detection Sequence Number Homology Homology to other
method size (bp) to pig M. bacteria
sequences hyorhinis sequence protein
Variable lipoprotein Random 191 100% none none
(vIp) cloning
16s/23s rRNA spacer Random 408 95% Mycoplasma
cloning hominis
88%
16s rRNA PCR 354 100% Mycoplasma
moatsii
97%
Putative transcription PCR 883 99% Mycoplasma Mycoplasma
elongation factor (tut) pulmonis pulmonis
79% 78%
Putative methylase Random 185 100% none Mycoplasma
cloning, mycoides
PCR 59%
Putative pyruvate Random 210 100% none Mycoplasma
dehydrogenase cloning, pulmonis
PCR 31%
Putative permease Random 130 100% none Mycoplasma
cloning, pneumoniae
PCR 19%
Trioso phosphate PCR 512 100% Mycoplasma Mycoplasma
isomerase (tpi) pneumoniae pulmonis
39% 56%
Silent and non-silent point mutations in tuf gene
, not applicable
:';
Fig. 9. Pathogen identifcation by genome sequence. Comparison of mycoplasma
phylogeneti and taxonomic markers (16s rRNA gene, a; and the 16s123s rRNA
intergenic spacer, b). The murine (M) mycoplasma (M-16s and M- 16s-23s) is highly
homologous to pig(P) Mycoplasma hyorhinis 
(specifically amplified P- 16s or 16s-23s .
reveals high sequence homology between the two isolates.
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spacer of the NCBI database , accession number AFI21891). Comparison of the variable
lipoprotein (vip) gene encoding a surface antigen (c) between mouse Mycoplasma
isolates (M-vlp) and pig 
Mycoplasma hyorhinis 
NCBI data base sequence AF193880
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Table III. Mvcoolasma-Infected Mice DeveloD Autoantibodies to Centrosomes
Experiment' Mycoplasma Numbers Proportion centrosomeinfection autoantibod - ositivenone n = 4 0% (n = 0)
5x 10 u. n= 12 50% n=6none n = 6 0% (n = 0)
5 x 10 f.u. n = 8 62.5% n = 5none n = 8 0% (n = 0)
5 x 10 u. n = 7 71.4% n = 
none n = 5 0% (n = 0)
5xl0 u. n=12 75% (n=9)
Experiments 1-4 performed in Balb.c/SvJ mice having the lowest prevalence of
spontaneous autoantibody development
a Control mice treated with 
antibiotic in expo 4
b An arbitrary assay cut-off value was chosen for a 3-4 fold change in titer
The Student t-test, two-tailed with unequal variances , was used for statistical comparison
between infected and uninfected mouse groups
Statistical
si nifcance
p-c 0.005
P-c0.
p-c 0.001
P-c0.
Fig. l0. Mycoplasma-infected mice develop anti-centrosome autoantibodies.
Immunofluorescent staining of centrosomes by anti-centrosome autoantibodies in sera of
mycoplasma-infected mice (a). Specific antibody to centrosome protein pericentrin
identifies centro somes (green) adjacent to dapi-staining cell nuclei(blue, b). In the
absence of autoantibodies in mouse sera( c), centrosomes are detected only by the
pericentrin antibody in the vicinity of dapi-staining nuclei (d ). Anti-centrosome IgM
autoantibody titers as detected by immunofluorescence do not differ significantly in
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mycoplasma-infected and uninfected mice 21 weeks post-infection (p=0.765 , p;;O.05)(e). 1"1
Mycoplasma-infected mice develop significantly higher titers of anti-centrosome IgG
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autoantibodies 21 weeks post-infection in contrast to uninfected mice ( p=0.OOI625) ( I).
Mouse autoantibody titers were determined by endpoint titration and are expressed as the
reciprocal of the serum dilution. Each point represents the result for an individual mouse.
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Results are representative of at least 4 independent experiments.
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Fig 11. Oral and intranasal, but not intravenous and intraperitoneal mycoplasma
infection induces the development of autoantibodies to the centrosome protein
pericentrin. Immunoblots of recombinant pericentrin: two 4-fold serially diluted serum
samples assayed for each mouse infected oral (a, lanes 1-8), intranasal (a, lanes 9- 16),
intravenous (b , lanes 1-8) and intraperitoneal (b, lanes 9- 16). Results are representative
of 3 experiments.
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Fig.12. Antibiotic treatment prevents the development of centrosome autoantibodies
in mycoplasma infected mice. When mice are treated with the bacteriostatic antibiotic
ciprofloxacin, autoantibodies to centro somes do not differ significantly in titer in
mycoplasma infected as compared to unnfected mice (P=0.6064). Positive control mice
that are not treated with antibiotic but infected with mycoplasma, develop significantly
higher autoantibody titers as compared to antibiotic-treated mice (P=0013).
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Fig.13. The autoantibody response amplifies to involve additional, endoplasmic
reticulum-associated auto antigens. Nine-eleven weeks after observing centrosome
autoreactivity in mycoplasma- infected mice, autoantibodies to a cytoplasmic antigen
were detected by IF (a). They co-localize with the endoplasmic reticulum protein
calnexin (b); cell nuclei are stained with dapi (c). Autoantibodies to the ER-associated
autoantigen have significantly higher titers in infected as compared to uninfected
mice(P=005206) (d). To compare titers of anti-centrosome antibodies (uninfected anti-
centrosome: UI- , infected anti-centrosome: I-C) with titers of antibodies to the ER-
associated autoantigen (uninfected anti-ER: UI- , infected anti-ER: I-ER) we used a
pan-specific antibody raised against immunoglobulin heavy and light chains. At any time
post-infection autoantibodies to the ER-associated autoantigen have lower titers
compared to anti-centrosome autoantibodies. Results are representative of 3 independent
experiments. Autoantibodies to the ER-associated autoantigen are of IgM isotype and
have significantly higher titers in infected as compared to uninfected mice (P=0.0059)
(e).
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CHAPTER IV
CONCLUSIONS, DISCUSSION AND FUTURE DIRECTIONS
A. Conclusions
1. Novel Methodology. These studies developed sensitive and specific assays to
determine the prevalence of anti-centrosome autoantibodies in patients with scleroderma.
2. Autoreactivity to Centrosomes in Scleroderma. Importantly, this analysis shows that
centrosome antigens are major scleroderma auto antigens and are at least ten-fold more
prevalent in patients than had been reported previously (Tuffanell et aI. , 1983). Only a
small percentage of normal individuals and patients with other connective tissue diseases
have centrosome autoreactivity.
3. Scleroderma Diagnosis. Among scleroderma patients with centrosome autoreactivity,
this work defines a subset that develop anti-centrosome antibodies, in the absence of
antibodies against other auto antigens diagnostically found in scleroderma, such as
topoisomerase I , centromeres etc. In these patients, anti-centrosome antibodies represent
the sole class of autoantibodies that is detectable. Taken together, these data suggest that
anti-centrosome autoantibodies may represent a new diagnostic tool in scleroderma
(Fauci, 2001-2002).
4. New Model. These studies induce experimentally the development of anti-centrosome
autoantibodies in mice. murine model was developed to study infection-induced
autoantibody production and this model was used to obtain information on:
5. Class-switching of centrosome autoantibodies from IgM to IgG isotypes and the
subsequent recruitment of new autoantibody specificities of IgM isotype.
6. Spreading of centrosome-specific autoreactivity to recruit additional, endoplasmic
reticulum autoantigens.
7. Murine Mycoplasma. These experiments isolate and characterize a murIne
mycoplasma able to induce autoantibody production upon infection of mice and provide
the opportunity to modify bacterial properties to address the mechanisms of autoantibody
development.
These results establish that centrosomes are major targets of autoantibodies in
scleroderma and also provide evidence that mycoplasmas trigger autoreactivity to
centro somes. The possible role of mycoplasmas as cofactors in the pathogenesis of
human autoimmune diseases is discussed below.
B. Discussion
Mycoplasmas Induce Autoantibodies. Numerous correlations in human patients
support a link between mycoplasma infection and the development of autoantibodies.
Individuals with M. pneumoniae infection can develop several autoantibody specificities
including autoantibodies to: brain, hear and muscle; erythrocyte I antigen; intermediate
filaments; mitotic spindle (Cassell et aI. , 2001-2002).
Mycoplasma-induced IgM autoantibodies specific for the I antigen of red blood cells are
able to trigger a self-limiting autoimmune hemolytic anemia (Cassell et aI. , 2001-2002).
Interestingly, similar oligoc1onal IgM autoantibody responses to endoplasmic reticulum
antigens that result upon mycoplasma infection are described in this disserttion. In
addition, our results are supported by descriptions of autoantibodies to centrosomes or
mitotic spindles in a few case reports of human infections with Mycoplasma pneumoniae
(Auer-Grumbach and Achleitner, 1994; Cimolai et aI., 1994; Lind et aI. , 1988). iil
nl!
Mycoplasmas Induce Chronic Inflammatory Disease. Mycoplasmas are good
candidates for co-factors in the development of rheumatic diseases. Mycoplasmas have
been incriminated in the development of human arhritis. An importnt basis for this
association is the fact that mycoplasmas trigger sterile arhritis in many animal species
including mice and rats (Mycoplasma arthritidis) , cattle (Mycoplasma bovis and
Mycoplasma mycoides), goats and sheep (Mycoplasma agalactiae and Mycoplasma
myco ides) , fowl (Mycoplasma gallsepticum 
and Mycoplasma synoviae) and pigs
(Mycoplasma hyorhinis and Mycoplasma hyosinoviae) 
(Tully and Whitcomb , 1979).
In rheumatoid arthritis patients, several studies reported the detection of mycoplasma
nucleic acid in the affected synovia but the results require furter substantiation (Razin et
aI. , 1998). Because mycoplasmas are commensal organisms and are frequently detected
in healthy individuals as well, their role as etiologic triggers of arthritis would require the
consistent detection of mycoplasmas in the chronic inflammatory lesion, ideally in
association with cells that can be incriminated as targets or effectors of an immune attack.
Definitive proof of mycoplasma-induced arthritis development would be provided by the
demonstration in an animal model of the pathogenic mechanism initiated by mycoplasma
infection that results in a phenotype identical to human rheumatoid arthritis. The work
described in this dissertation isolated a mycoplasma capable to induce in an animal host
connective tissue disease features other than arthritis, substantiating an additional link
between mycoplasma infection and autoimmunity.
Koch' s Postulates in Mycoplasma Infections. Mycoplasmas are considered commensal
organisms, acquired in utero, during or immediately after birth, that have low pathogenic
potential in healthy humans or animals (Baseman and Tully, 1997; Cassell, 1998).
Mycoplasma pathogenicity exacerbates in immunosuppressed individuals, including
prematue low-birth weight infants, patients with hypogammaglobulinemias of different
etiologies , AIDS patients and patients receiving immunosuppressive drugs (Baseman and
Tully, 1997; Cassell , 1998). Under these circumstances , an acute mycoplasma infection
may result either from the exacerbation in numbers of endogenous mycoplasmas, or from
de novo infection. Mycoplasmas evade immune defenses and antibiotic treatment by
multiple mechanisms and are not eradicated after acute infection. Therefore , the concept
of chronic mycoplasma infection would rather refer to the persistence of mycoplasma-
induced pathology, than to the mere presence of detectable mycoplasmas. Also
demonstrating Koch' s postulate concerning the ability of mycoplasmas to induce disease
would need to reproduce the conditions that confer commensal mycoplasmas a
pathogenic potential. Our results show that experimental inoculation of high numbers of
viable mycoplasmas is suffcient to induce in healthy mice scleroderma-like autoantibody
responses. The development of a full-blown scleroderma disease phenotype may require
not only exacerbations of mycoplasma numbers but possibly also host
immunosuppression. Also, fulfillment of the last of Koch' s postulates, requiring the
reisolation of the mycoplasma from autoantibody-positive mice, would need to employ
an in vitro tagged, transposon-mutagenized mycoplasma, that could be distinguishable
from endogenous mycoplasmas.
A Novel Murine Mycoplasma. The murine mycoplasma has high genome sequence
homology to the pig pathogen Mycoplasma hyorhinis. The isolation of Mycoplasma
hyorhinis from mice has not been reported previously. By this criterion, we have isolated
a novel murne mycoplasma. These findings expand the information on the natural
habitat of Mycoplasma hyorhinis. In support of this result, several mycoplasma species
including M hyorhinis have been previously isolated from more than one animal host
(Tully and Whtcomb, 1979). Interestingly, infection with Mycoplasma hyorhinis does
not induce any overt pathology in a number of mouse strains, but triggers pneumonitis
and arhritis in pigs. Mycoplasmas may be commensal in one animal host, while being
pathogens in another animal species. The zoonotic development of mycoplasma-induced
arhritis is an intriguing possibility.
The development of scleroderma-like autoantibodies to centrosome antigens upon
mycoplasma infection indicates a possible role for mycoplasmas as co-factors in the
development of scleroderma. A link between mycoplasma infection and scleroderma
development can be investigated by taking several approaches.
C. Future Directions
The results presented in this dissertation provide the basis for several future studies.
Define Additional Infectious Agents that May Induce Centrosome
Autoantibodies. It is important to establish whether the development of autoantibodies to
centro somes can be initiated only by mycoplasmas, generally by bacteria or by any
infectious agent including viruses or parasites. It is possible and likely that other
mycoplasmas, infecting mice or other animal species, have the ability to induce anti-
centrosome antibodies. It is also possible that other infectious agents including viruses
are capable to initiate an anti-centrosome antibody response. Viruses may have the ability
to directly induce the development of scleroderma-like autoantibodies or may
alternatively induce a host immunosuppression that would allow the exacerbation of
endogenous mycoplasmas, and these in tu may induce autoantibody development
(Naniche and Oldstone, 2000; Rouse and Horohov, 1986; Schneider-Schaulies et aI.
2001). Such hypotheses can be directly tested in the murine model developed in our
study. An intermediate role of endogenous mycoplasmas in the development of virus-
induced anti-centrosome autoantibodies can be distinguished by long-term antibiotic
treatment of virally infected mice. Antibiotic treatment is expected to prevent
autoantibody development induced by endogenous bacteria. The outcomes of this set of
experiments provide important insights into the opportunity of an antibiotic therapy for
scleroderma. We have already shown that antibiotic treatment prior and during
mycoplasma infection of mice abrogates anti-centrosome autoantibody development.
However, if infection with viruses or parasites can also induce scleroderma-like
autoantibodies, antibiotic treatment of scleroderma would unlikely be curative. The
findings of the proposed experiments would complete the information provided by a few
case reports describing remissions of scleroderma upon treatment with the antibiotics
minocycline and ciprofloxacine, which have bacteriostatic effects on mycoplasmas (Le et
aI. , 1998; Over and Bucknall, 1998).
2. Detect Tissue-Specific Autoantigens. A complete characterization of mycoplasma-
induced autoantibody responses would include the detection of possible organ-specific
autoantibodies. Mycoplasma pneumoniae has been associated with organ-specific
autoantibody development in patients (Cassell et aI. , 2001-2002). Several other infectious
agents have been shown induce experimentally organ-specific
autoantibodies(Barholomaeus et aI. , 1988; Olding et aI. , 1976). Autoantibodies to tissue-
specific auto antigens have been incriminated in organ-specific autoimmune pathogenesis.
In mice deficient in the aire gene , which directs ectopic thymic expression of tissue-
specific antigens and may promote thymic tolerance to self, organ-specific autoantibody
development accompanies lymphocytic infiltration that results in disease (Anderson 
aI. , 2002). The histological assay of mycoplasma-induced organ-specific autoantibody
responses could employ tissue substrates from alymphocytic mice deficient in the
recombinase-activating gene (Rag), to prevent interference with endogenous
immunoglobulins. The detection of organ-specific autoantibodies that occur as a
consequence of mycoplasma infection is a prerequisite in investigating their possible
potential to trigger scleroderma-like pathology (Section 4 , below).
Generate Pathogenic Infection-Induced Autoantibodies. Infection-induced
autoreactive B lymphocytes are normally short lived and destined to undergo apoptosis
(Ray et aI., 1996). Therefore, prolonging autoreactive B cell surival with the
accumulation of such cells above a critical numerical threshold may result in
autoantibody-mediated pathology. BLyS is a protein that has been recently demonstrated
to promote autoreactive B cell surival and autoantibody development (Gross et aI.
2001; Khare et aI. , 2000). Therefore , injection of recombinant BLyS in conjunction to
intranasal mycoplasma infection may greatly enhance the amplitude of the infection-
induced autoantibody response and possibly initiate pathology.
In addition, BLyS has been shown to promote isotype switching in the absence of T cells
(Litinskiy et aI. , 2002). In tu, isotype switching alters the ability of autoantibodies to
initiate tissue destruction by influencing their binding to Fc receptors and complement
(Azeredo da Silveira et aI. , 2002). We have shown that mycoplasma infection induces in
wild-type mice the development of class-switched autoantibodies of IgG 1 and IgG2b
isotypes, but not scleroderma-like pathology. BLyS-treatment that would accompany
mycoplasma-infection may confer infection-induced autoantibodies additional isotypes at
high titers, some of which may induce scleroderma-like pathogenesis.
4. Test the Pathogenic Potential of Infection-Induced Autoantibodies. It would be of
tremendous interest to establish whether the autoantibodies that develop upon
mycoplasma infection have the ability to induce a scleroderma-like pathology. As
mentioned above, autoreactive B lymphocytes generated during infection are normally
short lived and destined to undergo apoptosis, but can be employed to generate
hybridomas if fused to a bcl-2 expressing plasmacytoma (Ray et aI. , 1996). The rescue of
infection-induced autoreactive B lymphocytes and their transformation into antibody-
producing hybridomas may substitute for a pathologic amplification of autoantibody
titers, as it occurs during autoimmune disease. Monoclonal anti-centrosome
autoantibodies, enriched from hybridoma supernatants may have acquired the ability to
transfer disease to healthy recipients.
To directly test the pathogenic potential of autoreactive monoclonal antibodies with anti-
centrosome specificities, but also of monoclonal antibodies specific for ER-antigens or
possibly for tissue-specific antigens, hybridoma cells or supernatants would need to be
injected into healthy recipients. It is possible that the injection of a single monoclonal
antibody specificity is not sufficient to induce pathology, but that two or more
monoclonal antibodies binding different epitopes of the same auto antigen are required to
activate pathogenic immune effector cells, by cross-linng for example Fc-receptors on
their surface(Maccioni et aI. , 2002).
A demonstration of autoantibody-induced scleroderma-like pathogenesis in mice would
require a histological evidence of characteristic lesions, occuring subsequent to
autoantibody injection, in the organs affected by the human disease. Specifically, a
critical argument for autoantibody- induced pathogenesis would be the
immunohistochemical detection of scleroderma-like lympho-monocytic inflammatory
infitrates and, possibly, of injected monoclonal autoantibodies in such lesions.
Autoantibody-induced inflammation may subside upon discontinuation of autoantibody
inoculations or persist and develop into chronic scleroderma lesions (Matsumoto et aI.
2002). Scleroderma-like pathogenesis is expected to occur upon injection of autoreactive
monoclonal autoantibodies, but not upon injection of the same amount of an isotype-
matched anti-hapten monoclonal antibody control. Such findings can be directly
translated to the investigation of a possible role of pathogenic autoantibodies in the
development of human scleroderma. Anti-centrosome autoantibodies can be affnity-
purified from individual or pooled sera of scleroderma patients and used to immunize
mice to generate monoclonal anti-idiotype antibodies. Anti-idiotype antibodies would be
used for the subsequent immunohistochemical detection of anti-centrosome
autoantibodies in human scleroderma lesions.
5. Test for Mycoplasma Infection in Scleroderma. Finally, given that scleroderma
patients develop anti-centrosome autoantibodies and that anti-centrosome autoantibody
development in mice is due to a mycoplasma infection, a link between mycoplasma
infection and human scleroderma may possibly exist. It would be of interest to establish
whether scleroderma patients harbor mycoplasma nucleic acid, especially in affected
organs. Preliminary results obtained during the course of this study, demonstrating
amplification of mycoplasma sequences from the skin of scleroderma patients but not
from unaffected individuals , encourage this approach (Fig. 14).
Fig 14. Search for a human Mycoplasma in scleroderma. PCR primers were designed
based on pig (P) and mouse (M) Mycoplasma hyorhinis sequences of the transcription
elongation factor (tuf) gene (a), triosophosphate isomerase (tpi) gene (b) and 16S
ribosomal gene (c). Archived human skin was used as a source of DNA in an attempt to
amplify Mycoplasma tuf, tpi and 16s gene regions. Mycoplasma hyorhinis sequences
were amplified from 5 of 6 scleroderma patient samples (H, human mycoplasma
sequence), but from none of 6 basal cell carcinoma patients and none of 6 patients with
allergic skin reactions.
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D. Summary
This thesis research contributes to our understanding of autoantibody development by
defining:
1. the molecular identity of centrosome antigens targeted by autoantibodies in
scleroderma patients.
2. the development in scleroderma patients of autoantibodies to multiple antigens of
the same macromolecular centro somal complex, a prevalence pattern suggestive
of intermolecular epitope spreading.
3. the prevalence pattern of autoantibodies to centrosome antigens in relation to
human connective tissue diseases including scleroderma, SLE, Sjogren syndrome
and rheumatoid arthritis.
4. the specificities and isotypes of autoantibodies present in the natural repertoire of
unimunized mice.
5. the infection-induced development of oligoclonal , class-switched autoantibodies
il mIce.
6. the amplification of infection-induced autoantibody responses in mice to recruit
additional, oligoclonal autoantibody specificities of IgM isotype.
The work presented in this dissertation contributes to our understanding of scleroderma
by showing:
1. that the detection of antibodies to centro somes can orient the diagnosis of human
scleroderma, especially in the subset of patients that lack other autoantibody
specificities characteristic for the disease.
2. that scleroderma-like autoantibody responses can develop in mIce as a
consequence of infection, thus incriminating infection as a possible cofactor in
scleroderma etiology.
3. that loss of tolerance to centrosome antigens can initiate in mice scleroderma-like
autoimmune responses, thus providing an insight into scleroderma autoimmune
pathogenesis.
4. that autoantibodies to centrosomes are prevented from developing in mice by
antibiotic treatment prior and during mycoplasma infection, thus indicating the
possible value of a prophylactic antibiotic treatment of infections in scleroderma.
CHAPTER V
MATERIALS AND METHODS
A. Patients and Patient Sera
Sera from 129 patients with scleroderma-spectrum disorders who received medical care
at the University of Connecticut Health Center, or at the Hopital Notre-Dame in Montreal
were examined. Of these , 104 patients fulfilled the American College of Rheumatology
(ACR) criteria for scleroderma, 88 patients having proximal scleroderma and patients
having limited disease (1980). Twenty-one patients had CREST syndrome (two or more
featues: calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactily,
telangiectasias who do not fulfill criteria for SSc). Three patients had overlap syndrome:
one had proximal scleroderma and systemic lupus erythematosus, one had proximal
scleroderma and sicca syndrome , and one had CREST and sic ca. One patient had linear
scleroderma. Sera from these patients were stored at - C until use. The SSc sera were
tested previously for other autoantibodies including anti-nuclear antibodies (ANA), anti-
topoisomerase I , anti-centromere (ACA) , anti-double-stranded DNA, anti-small nuclear
ribonucleoproteins, and anti-Sm, anti- , and anti-Ro autoantibodies (Galperin et aI.
1996; Okano , 1996; Vazquez-Abad and Rothfield, 1995; Vazquez-Abad et aI. , 1994).
Sera from patients with other connective tissue diseases (systemic lupus erythematosus
rheumatoid arhritis, dermatomyositis, polymyositis, and Sjogren s syndrome) were
obtained from the University of Connecticut Health Center and from Dr. T. Medsger
(University of Pittsburgh). Normal sera were collected from blood donors at the
University of Connecticut Health Center and at the University of Massachusetts Medical
Center.
B. Mice and Mouse Sera
Balb.c/SvJ, C57BL/6J and 129/J mice were purchased from the Jackson Laboratories
(Bar Harbor, ME), Charles River Laboratories (Wilmington, MA) and Taconic Fars
(Germantown, NY). Uninfected mice were housed in a pathogen free facility, while
infected mice were housed under biocontainment conditions at the University of
Massachusetts Medical Center. Sera were also obtained from mouse colonies housed
under conventional conditions at the University of Massachusetts Medical Center and the
University of Connecticut Health Center.
C. Cell Lines and Tissue Culture
HepG2 is a human hepatoma cell line; 293T is a human epithelial kidney cell line;
NIH3T3 is a murine fibroblast cell line; SP2 is a murine plasmacytoma; Vero is 
fibroblast cell line derived from African green monkey kidney. Cells were maintained in
a 5%C02 incubator at 37 C in Dulbecco s minimal essential media (DMEM, Gibco
Grand Island, NY) supplemented with 100 U/ml of penicilin G (Gibco , Grand Island
NY), 100 f!g/ml streptomycin sulfate (Gibco, Grand Island, NY), 2 mM L-glutamine
(Gibco, Grand Island, NY) and 10% heat inactivated (56 , 30 min), certified
Mycoplasma-free fetal bovine seru (Gibco, Grand Island, NY). All tissue culture
reagents, trypsin (Gibco , Grand Island, NY) included, were tested for Mycoplasma
contamination using a commercially available PCR kit (Stratagene , La Jolla, CA).
D. Preparation of Recombinant Protein
We used cDNAs isolated in the original screen with SSc autoimmune serum that encoded
truncated forms of the centrosome proteins pericentrin (73 kD , clone "-1. 1) and centriolin
(CPI40, 75 kD) (Doxsey et aI. , 1994). Recombinant proteins were insoluble and were
purified as inclusion bodies as described (Doxsey et aI., 1994). Antibodies against the
bacterial fusion proteins were raised as described (Doxsey et aI., 1994). Recombinant
proteins served as autoantigens in the biochemical assays and antibodies were used in
double-label IF experiments.
E. Antibodies
Mouse monoclonal antibodies to Mycoplasma hyorhinis variable lipoprotein were a gift
of Dr. K. S. Wise of the University of Missouri. Rabbit polyclonal antibodies to
Mycoplasma hyorhinis were purchased from Cortex Biochem (San Leandro, CA). A
rabbit anti-pericentrin antibody was used as a centrosome marker. A rabbit anti-calnexin
antibody (Stressgen, Victoria, BC Canada) and a mouse monoclonal IgG2a anti-BiP
antibody (BD Biosciences, Franlin Lakes, NJ) were used as a markers for the
endoplasmic reticulum.
F. Immunoblotting
Fift micrograms of recombinant fusion protein was heated to 90 C in 200 l of sample
buffer for 3 min, subjected to electrophoresis on a 12% sodium dodecyl sulfate (SDS)-
polyacrylamide curtain gel (without wells), and transferred to Immobilon membrane
(Milipore Corporation, Bedford, MA) at 150 mA for 1 h in a semidry blotter (Fisher
Biotech, Pittsburgh, PA) at room temperature (RT). The membrane was incubated in Tris
buffered saline (TBS) pH 7.4 containing 1 % bovine serum albumin (BSA, Sigma, St.
Louis, MO) at RT for 60 min or at 4 C overnight. The membrane was then washed in
TBS with 0.05% Tween (TBST) for 20 min and subsequently incubated with patient sera
diluted to 1/250 in TBST-BSA at RT for 60 min. Assays of autoantibodies in mouse sera
employed serially diluted samples starting at a dilution of 1/40 in TBST-BSA at RT for
60 min. A multiwell miniblotter (Integrated Separation Systems, MA) was used to probe
56 sera at one time. The incubation step was followed by washing in TBST for 60
minutes with three changes. The membrane was incubated for 60 minutes at room
temperatue with horse radish peroxidase (HRP)-coupled anti-human secondary
antibodies (Sigma, St. Louis, MO) or anti mouse secondary antibodies (Amersham
Piscataway, NJ) and washed in TBS. Bound secondar antibodies were detected by
chemiluminescence according to the manufacturers protocol (Kirkegaard & Perr
Laboratories, Gaithersburg, MD ).
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G. Immunofluorescence
Human sera were assayed on cultured human cell substrates. HepG2 cells grown on
coverslips were washed twice in phosphate-buffered saline (PBS) pH 7.35 and
permeabilized in Pipes (80 mM), EGTA (5mM), MgCh (1mM), Triton X- I00 (0.5%) for
45 seconds at RT and fixed in methanol at - C for 5- 10 min. Fixed cells were washed
once in PBS and twice in PBS with 1% BSA and 0.5% Triton X-I00 (PBSAT) and
subsequently incubated with patient sera at a dilution of 1 :250 in a humidified chamber
for 40 minutes at R 
Mouse sera were assayed on cultured mouse NIH3T3 or monkey Vero cell substrates.
NIH3T3 cells or Vero cells were grown on coverslips, washed in PBS , pH 7.35 and fixed
in methanol at - C for 10 min or in 4% paraformaldehide (Electron Microscopy
Science, Ft. Washington, P A) in PBS at RT for 30 minutes. Fixed cells were washed in
PBS containing 0.1% BSA and 0.25% Triton X- I00 (PBSAT) and subsequently
incubated with freshly prepared serially diluted mouse sera in a humidified chamber for
40 min at RT.
Marker antibodies were incubated for 20 minutes at R 
Cells were washed 5- 10 times with PBSA T and subsequently incubated for 20 min with
fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG and Cy3-conjugated
donkey anti-human secondar antibodies (Jackson ImmunoResearch Laboratories , West
Grove, P A) or anti-mouse secondar antibodies (see below) at dilutions of 1 :500 in
PBSAT. Cy3-coupled donkey anti-mouse antibodies specific for IgG (H+L) or IgM were
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purchased from Jackson ImmunoResearch Laboratories (West Grove, PA), as were Cy3-
and biotin-coupled goat anti-mouse antibodies specific for Fcy used to detect
autoantibodies of IgG isotype, or Cy3-coupled anti-goat antibody used for signal
amplification in some experiments. Rat anti-mouse IgG 1 , IgG2a and IgG2b purchased
from Pharingen (San Diego , CA), rabbit and rat anti-mouse IgG 1 and IgG2b purchased
from Zymed (San Francisco, CA) were used to define autoantibody subclasses.
Secondar antibodies were washed 5- 10 times with PBSAT and once with PBS. Nuclear
DNA was stained with 4 diamidino- phenylindole (DAPI, 5pg/ml in PBS) for 1. min.
Coverslips were washed once with PBS , briefly with water, mounted using Vecta Shield
(Vector, Burlingame, CA) or ProLong Antifade kit (Molecular Probes, Eugene , OR) and
viewed on an Axiophot microscope (Zeiss, Germany).
Human samples were scored open-label and positive samples were confIrmed by a
second investigator. Comparisons between infected and unfected mouse groups were
scored open-label. Results were confrmed blindly by one or two investigators.
H. Virus and Mycoplasma Stocks
Herpes simplex virus I (KOS 1. 1 strain) and Sindbis virus stocks have been provided by
Dr. R. Welsh (University of Massachusetts Medical Center). To prepare stocks of murine
mycoplasma, Vero cell supernatants are harvested 7 days after inoculation with 10 pfu of
mycoplasma/T150 flask. After a preliminary centrifugation in closed 50 ml tubes at 2000
rpm, 4 oc for 20 min, infected supernatants are loaded gently on 1.5 ml cushions of 70%
renografin in PBS , added at the bottom of centrifuge tubes (25 x 89 mm, Beckman
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Instruents, Inc. , Palo Alto , CA) and centrifuged at 28,000 rpm in an SW28 rotor
(Beckman Instruments, Inc. , Palo Alto , CA) at 4 oC for 90 min. The fraction harested at
the renografin-media interface is subsequently added to the top of a 10-70% continuous
renografin gradient and centrifuged at 28 000 rpm in an SW28 rotor at 4 DC for 12 h. The
refractive index of gradient fractions is determined using a refractometer. Murine
mycoplasma stocks in sucrose, renografin or DMEM were maintained at -
Lyophilzed pig Mycoplasma hyorhinis was purchased from ATCC.
I. Mouse Infection
Six weeks old male or female mice were prebled and anesthetized each with 1 mg
Nembutal (Abbott Laboratories, Chicago , IL). Mice were infected intranasally with 10
pfuml of Ix or 4x plaque-purified inoculum of infectious agent that had been
parially purified on a renografin gradient (Squibb Diagnostics, New Bruswick, NJ) or
sedimented on a cushion of 70% sucrose in PBS. Centrosome autoantibody production
was observed at mycoplasma titers between 10 plaque-forming units (p. ). The
effciency of autoantibody production in experimental groups (50-75% of the animals)
did not increase at higher titers and was not observed below 10 u. Similar results
were observed in many mouse strains including Balb.c/SvJ, C57BL/6J and 129/J mice.
Control mice were inoculated intranasally with unnfected culture supernatant that had
been either spun on a renografin gradient or harvested at the sucrose interface. Mouse-to-
mouse contamination was avoided by using individual, disposable equipment, including
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restrainers. Inoculated mice were subsequently bled every 2 or 3 weeks and sera were
assayed for autoantibody development.Ciprofloxacin (20 I-g/ g body weight) was
delivered orally by gavage once per day.
J. Plaque Assay
To obtain organ homogenates, mouse spleens were placed in 1 ml of cold media and
homogenized in a mortar and pestle device. The spleen homogenates were centrifuged at
1075 x g (2000 rpm) at 4 C for 20 min to obtain clarified supernatants.
Freshly confluent cell mono layers were grown on 6-well plates. Ten-fold serial dilutions
of infectious agent inoculi were prepared. Diluted inoculi contained in 0. 1 ml were added
to 1 ml fresh media per well and cells were incubated for 90 min in a humidified 5%C02
incubator at 37 C. Monolayers were overlayed with 4 ml/well EMEM media (Eagle
modified essential media, BioWhttacker, Walkersvile, MD) containing 0.5% agarose
(SeaKem, BMA Rockland, ME) and supplemented with % certified Mycoplasma-free
fetal calf seru (Gibco, Grand Island, NY), 100 U/ml of penicilin G (Gibco, Grand
Island, NY), 100 flg/ml streptomycin sulfate (Gibco, Grand Island, NY), 2 mM L-
glutamine (Gibco , Grand Island, NY), and 2.5 U/ml nystatin (Gibco , Grand Island, NY).
Monolayers were incubated at 37 C and six days later 2 ml of 0.5% agarose in EMEM
containing 0.3 mg Neutral Red (Sigma, St. Louis, MO) were added to each well. For
mycoplasma titration, plaques were counted seven days post-inoculation. For Sindbis
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virus titration, plaques were counted 2 days post-inoculation. For herpes simplex virus I
titration, plaques were counted 3-4 days post-inoculation.
The murine mycoplasma grows in NIH3T3 , Vero, 293T and SP2 supernatants and
plaques on NIH3T3 , Vero and 293T monolayers. Ciprofloxacin (ICN Biomedicals
Irvine, CA) was used at a concentration of 0.5 f-g/ml. Doxicycline (Sigma, St. Louis
MO) was used at a concentration of 1 f-g/ml. Antibiotic was added to mycoplasma
infected cultues for 24 hours or 7 days and supernatants were subsequently titrated by
plaque assay.
K. Cloning, PCR, Sequencing and Sequence Alignments
DNA was extracted from gradient purfied murine mycoplasma and from lyophilized
Mycoplasma hyorhinis supplied by A TCC (Rockvile, MD) by using a proteinase K
digestion protocol (Qiagen Inc. , Valencia, CA). Genomic mycoplasma DNA was cleaved
with EcoRl or HindIII (N.E.B., Beverly, MA), the digest was visualized on 
agarose/TAE gels, purified and randomly cloned into pUC18 vector. Plasmid DNA from
individual clones was purified using QIAprepcolumns (Qiagen Inc. , Valencia, CA) and
the nucleotide sequences were determined using adequate vector primers at the DNA
Sequencing Facility of the University of Massachusetts Medical Center. NCBI databases
were searched for homologous sequences usmg BLASTX
...
(htt://ww.ncbi.nlm.nih.gov/blast). Comparing each mycoplasma sequence to public
databases resulted in a list of alignments. Primers were designed based on these
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alignments and the corresponding genes were specifically amplified from mouse and pig
Mycoplasma hyorhinis strains and compared. Primer sequences are as follows: for the
16s gene 5' -GGTT AAGTCCTGCAACGAGC- and
GTT AACTCACCGACTTTGGG-3 ' for the tuf gene
GGCTTGGTGCTGCTCAA TGGA-3' and 5' -CCT ACAGTTCT ACCACCTTCACGG-
; for the putative methylase gene 5' GATAATACAAGAAGTGGTTTATTGC -3' and
AAAACTTTCCAACTCGAGTT- ATATCC- ; for the putative dehydrogenase gene
5' - TGAAGAACTTT AGATGTTTCAACAACTCC- and
TCCTGTTGA TTTTTCT ACA TTC- for the putative permease gene
CCAGTTTTTGTAGA T A TT AAGAA TCG- and
CTGTAGCTGCAAAATCC- ; for the tpi gene 5' ATTTGGATTTTGCAATTGC-
and 5' TTTTCTTGCGAACTGAGCCAACC -
Each PCR reaction was prepared in a laminar flow PCR hood (AirClean, Raleigh, NC)
and used 50 pmol of each primer, 5U of HotStarTaq polymerase (Qiagen Inc. , Valencia
CA), 100 mM of each deoxynucleotide triphosphate, in 67 mM Tris buffer (pH8.8), 4
mM MgCI2, 16 mM (NH S04, 10mM 2-mercaptoethanol and 100 (g/ml bovine serum
albumin, BSA).
PCR amplifications were performed at 95 oC for 5 min (1 cycle), 94 oC for 1 min, 50 o
for 2 min, 72 oC for 1 min (40 cycles) and 72 oC for 5 min (1 cycle). Amplifications were
caried out in an MJ Thermocycler (MJ Research, Watertown, MA). Gel purified PCR
amplification products were cloned using a T A cloning system (Invitrogen, Carlsbad
JA.
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CA) according to the manufacturer s instructions. PCR detections of mycoplasma in
mouse tissue were performed by two independent investigators.
L. Electron microscopy
After plaque-formation, monolayers were fixed and embedded in situ. Mycoplasma was
pelleted from enriched gradient fractions, fixed and embedded. Fixation was performed
in 4% paraformaldehide (Electron Microscopy Science, Ft. Washington, PA) in PBS at
RT for 30 minutes. Samples were processed for electron microscopy as described
(Doxsey et aI. , 1994). Thin sections (500-700 nm) of the embedded samples were cut on
Sorvall ultramicrotome, stained with uranyl acetate and lead citrate (Ted Pella
Incorporated, Redding, CA) and viewed in a JOEL electron microscope(Doxsey et aI.
1994).
M. Statistical Analysis
Analysis of human patient groups. The Z test was used to determine whether statistical
differences existed between (a) the proportion of SSc patients and normal individuals
auto reactive to centrosome proteins, (b) the proportion of SSc patients and patients with
other connective tissue diseases auto reactive to centrosome proteins, and (c) the
proportion of normal individuals with ANA and those autoreactive to centrosome
107
proteins. The chi-square test was used as an independence test to compare the results
obtained by IF with the results obtained by immunoblotting for the same groups of SSc
patients listed above. The chi-square test was also used to compare the numbers of
patients positive for centrosome autoantibodies that had different forms of the disease or
different clinical disease features. Sensitivity and specificity of diagnostic tests were
calculated using our results and published data according to published definitions and
formulas (Knapp and Miler, 1992; Vazquez-Abad and Rothfield, 1995).
Statistical analysis mouse seru autoantibody titers was performed using an Epi Info 6.
softare package. Comparisons between autoantibody titers in infected and uninfected
mice were performed using the Mann-Whitney test. The Student t-test, two-tailed with
unequal variances was used where appropriate.
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